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Abstract: Determination of true IGF-I bioactivity in serum and other 
biological fluids is still a  substantial challenge. The IGF-IR Kinase 
Receptor Activation assay (IGF-IR KIRA assay) is a novel tool to asses 
IGF-IR stimulating activity (IRSA) and has opened a new era in studying 
the IGF system. In this paper we discuss many studies showing that 
measuring IRSA by the IGF-IR KIRA assay often provides fundamentally 
different information about the IGF system than the commonly used total 
IGF-I immunoassays. With the IGF-IR KIRA assay phosphorylation of 
tyrosine residues of the IGF-IR is used as read out to quantify IRSA in 
unknown (serum) samples. The IGF-IR KIRA assay gives information about 
net overall effects of circulating IGF-I, IGF-II, IGFBPs and IGFBP-
proteases on IGF-IR activation and seems especially  superior to 
immunoreactive  total IGF-I  in monitoring therapeutic interventions. 
Although the IRSA as measured by the IGF-IR KIRA assay probably more 
closely reflects true bioactive IGF-I than  measurements of total IGF-I 
in serum, the IGF-IR KIRA assay in its current form does not give 
information about all the post-receptor intracellular events mediated by 
the IGF-IR. Interestingly, in several conditions in health and disease 
IRSA measured by the IGF-IR KIRA assay is considerably higher in 
interstitial fluid and ascites than in serum. This suggests that  both 
the paracrine (local) and endocrine (circulating) IRSA should be measured 
to get a complete picture  about  the role of the IGF system in health 
and disease. 
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Responses to the Review of GHIR-D-19-00026– Janssen et al.  -The Insulin-like Growth 
Factor-I Receptor Stimulating Activity (IRSA) in Health and Disease. 
 
 
Reviewer 1 
 
Dr. Janssen and coworkers have written an elegant review on IRSA in health and disease. The 
manuscript is timely and easy to read. As stated by the authors, "the measurement of IRSA by 
the IGF-IR KIRA assay has opened a completely new era and is a novel tool to asses 
circulating IGF-I bioactivity". 
 
 
Thank you for your kind words and the careful review of the manuscript.  
 
We have completed our revisions based on the Reviewer‘s helpful comments, and below we 
indicate point by point the changes we made to the manuscript. 
 
 
Answers to comments of Reviewer 1: 
 
1.First.- 6.4 IRSA and PAPP-A2 (lines 383-385): "In both families loss-of-function mutations 
in the PAPP-A2 gene were found which resulted in undetectable PAPP-A2 activity [17]". This 
is not correct. In effect, while the Spanish patients exhibit a mutation with a stop codon 
(hence, PAPP-A2 serum levels were undetectable), the patients of Palestinian origin (second 
family) exhibited low levels of PAPP-A2, but detectable low PAPP-A2 and PAPP-A2 activity. 
Please, modify it in the manuscript accordingly. 
 
 
A: Thank you very much for this useful addition. In the revised manuscript this was modified 
accordingly (see page 17, lines 399-401).  
 
2. Second.- When the authors analyzed the results of IRSA in anorexia nervosa and obesity, it 
would be of interest to indicate that measuring PAPP-A and PAPP-A2 activity could be of 
help to understand, their differences in circulating IRSA (measured by KIRA assay), total 
IGF-I and free IGF-I. 
 
A: Thank you very much for this suggestion. However, to our knowledge the role of PAPP-A  
and the  IGF system has not yet been studied in anorexia nervosa (see Støving RK. 
MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical 
update. Eur J Endocrinol. 2019;180 :R9-R27).  
.  
 
In the revised manuscript we added the following to the paragraph about IRSA and Anorexia 
Nervosa (page 18, lines 428-430):  
 
Measuring PAPP-A and PAPP-A2 activity could be of potential value to understand 
differences in circulating IRSA (measured by KIRA assay), total IGF-I and free IGF-I in 
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anorexia nervosa. However to our knowledge the role of PAPP-A and the IGF system in 
anorexia nervosa has not yet been studied.  
 
Ref 75. Støving RK. MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and 
endocrinology: a clinical update. Eur J Endocrinol. 2019; 180(1):R9-R27 was added to the 
reference list. 
 
Concerning a potential role of PAPP-A on the IGF system in obesity we added the following 
to the paragraph about IRS and Obesity (page 19, lines 441-444): 
 
It has been hypothesized that the observed increased ability of media harvested from visceral 
adipose tissue (VAT) to activate the IGF-IR in vitro (measured by the KIRA assay) is 
secondary to an upregulated PAPP-A mediated release of IGFBP-4 complexed IGF (Gude et 
al. PAPP-A, IGFBP-4 and IGF-II are secreted by human adipose tissue cultures in a depot-
specific manner. Eur J Endocrinol. 2016; 175: 509-519.  However, it is at present unclear 
whether local PAPP-A translates into differences of circulating IRSA in human subjects with 
obesity.  
 
 
3. Third.- 6.18 IRSA, Lung Cancer and Pleural Fluid (lines 598 & 599): The authors state "In 
addition, PAPP-A, an IGFBP protease, that may cleave IGFBP-4 and IGFBP-5, was elevated 
in pleural fluid and it was speculated by the authors that IGFBP-proteases (inclusive PAPP-
A )". Question: What is the evidence suggesting that PAPP-A may cleave IGFBP-5? It is 
generally  reported that PAPP-A selectively cleaves IGFBP-4. Thank you for your comment. 
 
 
A] Overgaard et al (1) and Laursen et al. (2) have both published evidence that PAPP-A may 
cleave IGFBP-5. The specificity of PAPP-A and PAPP towards the six different IGFBPs was 
recently summarized by Claus Oxvig (see Table 1 in (3)). These three references (49, 59, and 
60) were added to the revised paper (page 27, lines 624-625). 
 
 
Ref 49. Laursen LS, Overgaard MT, Søe R, Boldt HB, Sottrup-Jensen L, Giudice LC, 
Conover CA, Oxvig C Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like 
growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism 
of IGFBP-4 proteolysis by PAPP-A. FEBS Lett. 2001; 504:36-40. 
 
Ref 59. Overgaard MT1, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C. 
Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-
binding protein-5 proteinase. J Biol Chem. 2001; 276(24):21849-53 
 
Ref 60. Oxvig C. The role of PAPP-A in the IGF system: location, location, location. 
J Cell Commun Signal. 2015 Jun; 9(2):177-87 
 
 
4. Fourth.- 6.21 IRSA and Longevity: It is well known that patients with GH resistance (Laron 
Syndrome) and low or undetectable levels of total and free IGF-I are associated with 
longevity. Are there any results available regarding IRSA (measured by KIRA assay) in 
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patients with Laron syndrome? Could you, please, add a sentence in this Section related to 
these patients? Thank you. 
 
A] To our knowledge to date are no data available regarding IRSA (measured by KIRA assay) 
in patients with Laron Syndrome. In the revised manuscript we added the following (page 15, 
lines 359-364): 
 
To our best knowledge to date no data are available whether serum IRSA measured by KIRA 
assay is also reduced in subjects with Laron Syndrome. Using a porcine cartilage bioassay it 
has been found that serum IRSA in subjects with Laron Syndrome appeared to relate not 
directly to serum total IGF-I levels, but to the effects of the various IGFBPs on the bound 
IGFs (18). It was suggested that the regulation and perhaps also degradation of the IGFBPs 
play an important role in the regulation an availability of IGF-II in Laron Syndrome.  
 
 
Ref 18. Cotterill AM1, Holly JM, Taylor AM, Davies SC, Coulson VJ, Preece MA, Wass JA, 
Savage MO. The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in 
Laron-type dwarfism. J Clin Endocrinol Metab. 1992; 74:56-63 was added to the Reference 
list. 
 
We previously measured IRSA by KIRA assay in centenarians and found relatively low IRSA. 
Mean IRSA in 106 centenarians was 132 (107-157pmol/L) (mean (25
th
-75
th
 percentile)), 
while mean IRSA in 192 centenarians’ offspring and 80 offspring matched controls were 144 
(119-170) pmol/L and 161 (134-187) pmol/L. In addition, centenarians showed a 2-fold 
higher insulin sensitivity than centenarians’ offspring. Therefore we hypothesized that, 
despite low circulating IRSA, the post-receptor signaling pathways of the IGF-IR was up-
regulated in centenarians. This information was also added to the revised manuscript (page 29, 
lines 661-666). 
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Responses to Review of GHIR-D-19-00026– Janssen et al.  -The Insulin-like Growth 
Factor-I Receptor Stimulating Activity (IRSA) in Health and Disease. 
 
 
 
This is an extremely well-written and comprehensive review on the IRSA and important 
health outcomes. The authors are commended on a timely and informative review that will be 
well received in the literature and should spur more interest in IGF-I physiology and 
measurement. 
 
A: We appreciate your kind words and the careful review of the manuscript.  
 
We have completed our revisions based on the Reviewer‘s helpful comments, and below we 
indicate point by point the changes we made to the manuscript. 
 
Answers to comments of Reviewer 2: 
 
1] Can the authors make any recommendations or statements on which commercially IGF-I assay is 
superior? 
 
A] Unfortunately there are no commercially assays available to measure IRSA by KIRA. This is one of 
the important steps to be taken to implement wide use-spread use of the KIRA assay (see also point 
6 below).  
Although there are several immunoassays commercially available to measure Total and Free IGF-I, 
none of these latter assays generate information about modifying effects of IGBPs and IGFBP 
proteases on IGF-I action while it is generally accepted that bioactivity at the level of the IGF-IR is 
modulated by the IGFBPs and IGFBP proteases.  
 
 
2] Can the authors provide a bit more explanation on the modulating effects of IGFBPs on IGF-I 
action? 
 
A] We did follow this  suggestion and added  in the revised manuscript the following information  
(page 4, lines 103-106):  
The IGFBPs were initially defined as serum carriers and passive inhibitors of IGF actions. However, it 
has been repeatedly demonstrated  that IGFBPs  not only inhibit IGF actions in many circumstances  
but they may also potentiate IGF-I actions. IGFBPs are widely expressed in almost all tissues of the 
body , and function as  flexible endocrine and autocrine/paracrine regulators of IGF-I bioactivity.  
 
Reference 3  (L.A. Bach, IGF-binding proteins, J Mol Endocrinol, 61 (2018) T11-T28) was added to the 
Reference list 
 
3] I recommend referring to concentration rather than levels as concentrations are measured in units. 
 
A] Thank you. We followed this suggestion  and changed levels in concentrations through the whole 
paper. 
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4] Do the authors believe the studies with IRSA and exercise are definitive or are more studies perhaps 
needed? 
 
A] Thank you for this question. We do not think that the studies about IRSA and exercise are 
definitive.  Although the discussed studies suggest no significant changes of circulating IRSA during 
acute and chronic exercise , these observations, however, should not be interpreted that IRSA lacks 
importance or relevance in exercise.  Although  local IGF-I activity I has been  found consistently  
upregulated with both acute and chronic exercises,   at presence the precise and relative role of 
systemic versus locally produced IGF-I and  physical activity is still not clear. Thus in future research  
samples in the body ‘s various compartments (blood, interstitial fluid, muscle) should be collected to 
measure IRSA during a variety of acute and chronic conditions of exercise.  
 
This information was added to the revised manuscript at page 10, lines 249-253 and page 11, lines 
254 -255). 
 
5] I think the authors will be well served by also highlighting the studies that have measured free IGF-I 
and have shown higher relationships with health outcomes than total IGF-I. This will further reinforce 
their overall concept on the importance of IGF-I measurement.  
 
A] Thank you for this suggestion. However, we decided not to follow this suggestion.  
 
Although we agree that studies measuring  free IGF-I have shown higher relationships with health 
outcomes than total IGF-I, neither the ultrafiltration nor the direct immunoassay to measure free 
IGF-I take the modifying effects of IGFBPs and IGFBP proteases on the interaction between IGF-I and 
the IGF-IR into account.                                                                                                                                             
 
In addition,  the relationship of free IGF-I  and total IGF-I with a variety health outcomes was 
previously extensively reviewed by Jan Frystyk in this Journal ( Frystyk J. Free insulin-like growth 
factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. 
Growth Horm IGF Res. 2004 Oct;14(5):337-75 
 
 
6] What are some potential next steps for the KIRA and what would need to occur to implement wide-
spread use? 
 
 
A] Thank you for raising this important issue. In the first version we had already briefly 
discussed some potential next steps for the KIRA (page 30, line 702 and page 31, lines 703-
706) In the revised version of the manuscript we added the following information at page 32, 
lines 744-751  and page 33, lines 752-755. 
 
Easy access and reliability of a  cell line transfected with the  human IGF-IR are prerequisites 
to implement wide-spread use of the KIRA assay. Cells transfected with the  human IGF-IR 
frozen in microwell plates offer a potential valid alternative to fresh cells from a growing 
culture. When these plates can be used immediately after thawing and the frozen cells can be 
revitalised without passaging and washing cells,  total time needed to perform the assay is 
considerably shortened. This strategy may further help to overcome an important bottleneck 
to implement wide-spread use of the KIRA assay; it removes day-to-day variation, eliminates 
passage effects and improves consistency of cell-based assay results. The production of these 
frozen cells should be standardised so that different batches are highly comparable. Freezing 
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and resuscitation protocols should be optimized, and the performance of these ready-to-use 
cells should be compared with those from continuous culture to determine whether they could 
be used as a replacement To further reduce costs and consistency of the KIRA the antibodies 
should be replaced by aptamers.  
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Abstract 27 
Determination of true IGF-I bioactivity in serum and other biological fluids is still a substantial challenge. 28 
The IGF-IR Kinase Receptor Activation assay (IGF-IR KIRA assay) is a novel tool to asses IGF-IR stimulating 29 
activity (IRSA) and has opened a new era in studying the IGF system. In this paper we discuss many 30 
studies showing that measuring IRSA by the IGF-IR KIRA assay often provides fundamentally different 31 
information about the IGF system than the commonly used total IGF-I immunoassays. With the IGF-IR 32 
KIRA assay phosphorylation of tyrosine residues of the IGF-IR is used as read out to quantify IRSA in 33 
unknown (serum) samples. The IGF-IR KIRA assay gives information about net overall effects of 34 
circulating IGF-I, IGF-II, IGFBPs and IGFBP-proteases on IGF-IR activation and seems especially superior 35 
to immunoreactive total IGF-I in monitoring therapeutic interventions. Although the IRSA as measured 36 
by the IGF-IR KIRA assay probably more closely reflects true bioactive IGF-I than  measurements of total 37 
IGF-I in serum, the IGF-IR KIRA assay in its current form does not give information about all the post-38 
receptor intracellular events mediated by the IGF-IR. Interestingly, in several conditions in health and 39 
disease IRSA measured by the IGF-IR KIRA assay is considerably higher in interstitial fluid and ascites 40 
than in serum. This suggests that both the paracrine (local) and endocrine (circulating) IRSA should be 41 
measured to get a complete picture about the role of the IGF system in health and disease. 42 
 43 
Keywords: IGF-I, IGF-I receptor, IGF-I Bioactivity, KIRA, Immunoassays, Endocrine, Paracrine, Health, 44 
Disease 45 
 46 
 47 
 48 
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1.Introduction 94 
Insulin-like growth factor-I (IGF-I) is tightly bound by six high affinity IGF binding proteins (IGFBP-1-6) in 95 
the circulation. In healthy subjects, approximately 95% of all circulating total IGF-I is present as a ternary 96 
complex formed by IGF-I, IGFBP-3 and acid labile subunit (ALS), making this complex quantitatively the 97 
most important, while the remaining IGF-I circulates in a free form (<1%) or as binary complexes 98 
(approximately 4–5%) [17]. It is assumed that free IGF-I is the only  form of IGF-I which is able to directly 99 
stimulate the IGF-IR [42] (See Figure 1 for more details). Activation of the insulin-like growth factor-I 100 
receptor (IGF-IR) by free IGF-I stimulates multiple pathways which finally results in multiple biological 101 
effects in a variety of tissues and cells (Figure 2).                                                                                                                                                                  102 
The IGFBPs  were initially defined as serum carriers and passive inhibitors of IGF actions [3]. However, it 103 
has been repeatedly demonstrated  that IGFBPs  not only inhibit IGF actions in many circumstances,   104 
but they may also potentiate IGF-I actions [3]. IGFBPs are widely expressed in almost all tissues of the 105 
body , and function as  flexible endocrine and autocrine/paracrine regulators of IGF-I bioactivity [3].                                                                                      106 
Determination of true IGF-I bioactivity in serum and other biological fluids still presents substantial 107 
challenges. After generation of highly specific antibodies for IGF-I it became possible to develop 108 
immunoassays for assessment of circulating IGF-I levels in serum and plasma [31, 69, 95]. To date total 109 
IGF-I immunoassays are clinically widely used to assess circulating IGF-I bioactivity in humans and the 110 
majority of available literature about IGF-I is based on information obtained by use of immunoassays.   111 
As a consequence, immunoassays are very often considered to be the most useful method to assess the 112 
amount of circulating IGF-I that is biologically active in the body. However, in the following paragraphs 113 
several arguments will be discussed, which will challenge this view.                                                                                                                                                               114 
A major technical problem encountered when measuring circulating IGF-I by immunoassays is 115 
interference of IGFBPs.  Presence of IGFBPs in a blood sample may significantly disturb reactions 116 
between IGF-I and antibodies in the tube and this may result in spurious estimates of the total amount 117 
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of IGF-I present in that sample. Therefore, most available IGF-I immunoassays use an extraction step to 118 
remove all IGFBPs prior to the measurement in order to guarantee full accessibility to IGF-I of highly 119 
specific antibodies targeting IGF-I [16]. However, by removing all IGFBPs before measurement of IGF-I 120 
(potentially) modulating effects of IGFBPs and IGFBP proteases on IGF-IR stimulating activity  (IRSA)  are 121 
also eliminated [62]. Thus, as a direct consequence of the just discussed pre-analytical procedure, total 122 
IGF-I immunoassays are unable to produce any information about directly modulating effects of IGFBPs 123 
or IGFBP-proteases on IRSA.                                                                                                                            124 
Moreover, total IGF-I immunoassays determine the immuno-reactive properties of circulating IGF-I-like 125 
molecules, rather than the direct (stimulating) effects  of these molecules on the IGF-IR [6].  In addition, 126 
total IGF-I immunoassays may recognize  IGF-I isoforms that  are less bioactive and able to stimulate the 127 
IGF-IR than wild type  IGF-I [6].  Moreover,  fragments of IGF-I that lack biological actions, may still 128 
harbor epitopes that can be recognized by antibodies targeted to IGF-I  and be measured as intact IGF-I 129 
by  total  IGF-I immunoassays [6].  It has been further suggested that altered post-sampling integrity of 130 
IGF-I in vitro might contribute to the reported inconsistencies in circulating total IGF-I levels in literature. 131 
This latter phenomenon occurs especially under pathologic conditions [42]. Results of  total IGF-I 132 
immunoassays can be  further disturbed by presence of so called heterophilic antibodies in serum  133 
which may result in both falsely higher or lower total IGF-I levels  [7]. Despite all these limitations total 134 
IGF-I immunoassays have become popular in the last 40 years to monitor circulating IRSA in blood 135 
samples. 136 
 137 
2. The history of measuring IRSA by bioassays 138 
Any intracellular point stimulated by binding of IGF-I to the IGF-I receptor may be utilized for the 139 
development of an IGF-I bioassay [66]. In the past a variety of tissues and cells have been used as target 140 
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organs in bioassays for the determination of IRSA. Salmon and Daughhaday used the incorporation of 141 
[35S] sulphate into hypophysectomized rat cartilage [67]. Other bioassays used chicken embryo, 142 
weanling or fasted rats or porcine cartilage to assess incorporation of sulphate [36, 81, 93]. In the fat 143 
pad bioassay the conversion of [14C] glucose to CO2 was used to assess IRSA, while in another bioassay 144 
incorporation of tritiated thymidine into DNA  of embryonic chicken fibroblasts was used [26, 61]. 145 
Although all these traditional IGF bioassays were advantageous in biological relevance, they showed 146 
certain failings in their use: lack of sensitivity, precision and specificity; in addition, high variability and 147 
long assay duration (3-6 days); comparable phenotypic responses could be the consequence of 148 
activation of an alternative receptor (e.g. the insulin receptor) [37, 66].  Results of many of these 149 
traditional bioassays were sometimes also influenced by other hormones, which were present in the 150 
measured serum samples [37]. For example, it was observed that thyroid hormone (like IGF-I) could 151 
stimulate sulphate uptake in to chicken embryo cartilage whereas cortisol was found to inhibit IGF-I-152 
mediated effects in porcine cartilage [22, 27]. Moreover, these traditional IGF bioassays did not detect 153 
specifically the IRSA  in whole serum, but rather reflected the overall stimulating activity of serum for 154 
that target tissue [37]. 155 
 156 
3. The development of the IGF-I Receptor Kinase Receptor Activation Assay (KIRA) 157 
The IGF-IR KIRA assay was developed by Michael Sadick et al. as an alternative approach for bioassays 158 
measuring IGF-IR endpoints [66]. They showed that results obtained with an IGF-IR KIRA assay in MC-7 159 
cells (with endogenous IGF-IR expression) correlated well with classical endpoint bioassays such as a 160 
[3H]thymidine incorporation assay [66]. The principle of the IGF-IR KIRA assay is based on measurement 161 
and quantification of phosphorylated tyrosine residues of the -subunit of the IGF-IR (Figure 3).  162 
Phosphorylation of tyrosine residues of the β-subunit of the IGF-IR normally starts the intracellular signal 163 
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cascade after binding of IGF-I to the IGF-IR [14, 66]. The IGF-IR KIRA assay utilizes two separate 164 
microtiter plates, one for ligand stimulation of intact cells, and the other for receptor capture and 165 
phosphotyrosine ELISA [66] (Figure 3). Results obtained with the IGF-IR KIRA assays are highly 166 
reproducible [66].  Since the IGF-IR KIRA assay uses a sample incubation time of 15 minutes, time is too 167 
short for stimulated cells to produce de novo IGFBPs that may interfere with IGF-I action during sample 168 
incubation [14]. The IGF-IR KIRA assay makes use of either endogenously expressed IGF-IR receptors or 169 
stably transfected IGF-IR receptors with a polypeptide flag (11). Frystyk et al. and Brugts et al. used an 170 
IGF-I KIRA assay with human embryonic cells transfected with a copy DNA of the full-length human IGF-171 
IR [8, 14]. By this modification the IGF-IR KIRA assay became even more sensitive than that original KIRA 172 
assay described by Sadick et al. Most likely this was due to the higher expression of IGF-IRs after 173 
transfection compared to endogenously expressed IGF-IRs [14]. The standard curve of the IGF-I KIRA 174 
based on human embryonic kidney (HEK293) cells transfected with a copy DNA of the full-length human 175 
IGF-IR started at a concentration of 10 pmol/L (0.08 µg/L) IGF-I [14]. The IGF-IR KIRA assay was found to 176 
be specific: insulin, insulin analogs and proinsulin in physiological concentrations had almost no 177 
(stimulating) effect on the IGF-IR KIRA signal while IGF-II had a cross-reactivity of 12% [14]. In addition, it 178 
had a remarkable low intra- and inter-assay coefficient variation <15%) for a bioassay  [8]. It has been 179 
further demonstrated that the IGF-IR KIRA is a relatively rapid and reproducible method for assessing 180 
IRSA  which takes into account modifying effects of IGFBPs on the interaction between IGF-I and the IGF-181 
IR [41].                                                                                                                                                                                         182 
In the next paragraphs we will give a comprehensive overview of the existing literature which illustrates 183 
the clinical significance of measuring IRSA by the IGF-IR KIRA assay. 184 
 185 
4. IRSA and age 186 
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To date only one study has established age-specific normative values  for IRSA as measured by the IGF-IR 187 
KIRA assay [8]. In a cross-sectional study circulating IRSA was measured in 400 healthy non-fasting blood 188 
donors aged 18-79 yrs. [8]. Circulating IRSA showed a wide inter-individual variability among subjects at 189 
every age. Like total IGF-I concentrations, IRSA decreased significantly with age but the decline of IRSA 190 
with age was less steep than it was observed for circulating total IGF-I concentrations [8]. Due to the 191 
cross-sectional design of this latter study no information about intra-individual changes of IRSA during 192 
aging was obtained. Nevertheless the discrepant decline with age between IRSA and total IGF-I suggests 193 
that IRSA becomes less growth hormone (GH) dependent with aging than total IGF-I concentrations [8]. 194 
Other potential explanations for this  discrepant decline with age between IRSA and total IGF-I could be 195 
that the relative increase in IRSA with age compared to total IGF-I reflects a compensatory mechanism 196 
to overcome an age-dependent relative IGF-IR resistance or that the relative contribution of IGF-II to 197 
IRSA increases with age  [8].                                                                                                                                                                                198 
In the same study a significant drop in IRSA was observed in women aged 50-60 years which was not 199 
observed for total IGF-I [8].  Women at younger ages showed higher lRSA than males but had lower IRSA 200 
than the males after the age of 50-60 years. The  decrease in estrogen levels around menopause in 201 
females might play a role in the observed drop in IRSA after the age of 50-60 years since  estrogen is well 202 
known to play an important role in regulating activity of the GH/IGF-I axis [50].                                                                   203 
IRSA as measured by the IGF-IR KIRA assay was positively related to total IGF-I but the found correlation 204 
coefficients were relatively low (r  0.50) suggesting that IRSA as measured by the IGF-IR KIRA assay 205 
produces basically different information about the IGF-I system than IGF-I immunoassays [8]. However, 206 
the physiological importance of this difference is unclear at the moment.                                                                                                                                                        207 
In another smaller cross-sectional study of men and women aged 20-70 yrs. IRSA also tended to 208 
decrease to a lesser extent than total IGF-I with age [91]. However, in this latter study no significant 209 
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drop of IRSA around menopause was found in females, which may be related to the lower number of 210 
participants included in this latter study [91].   211 
 212 
5. IRSA in Health 213 
5.1 IRSA and Fasting 214 
In a small study in which in non-obese healthy subjects effects of fasting on GH signaling and action 215 
were investigated, GH concentrations significantly increased after 37.5 h of fasting compared to levels 216 
after the overnight fast, while (immuno-reactive) total IGF-I concentrations were similar under both 217 
conditions [55]. In contrast, IRSA measured by the IGF-IR KIRA assay was significantly lower after 37.5 h 218 
of fasting compared to results following the overnight fast, whereas IGFBP-1 was significantly increased 219 
[55]. These findings are in line with Chen et al. who previously reported that after prolonged fasting 220 
reductions of total IGF-I were preceded by reductions in IRSA and free IGF-I and a simultaneous increase 221 
of IGFBP-1 concentrations [13]. Thus this time course suggests that the decline in IRSA was causally 222 
linked to the increase in IGFBP-1 [55]. In this latter study it was also found that IRSA compared to ultra-223 
filtered free IGF-I was relatively less affected by fasting and it  was hypothesized that this latter finding 224 
could be explained by the fact that in contrast to the ultrafiltration method the IGF-IR KIRA assay was 225 
able to detect the concomitant increase in IGFBP-1-complexed-IGF-I [13]. 226 
 227 
5.2. IRSA and Life style factors 228 
When in a cohort of young women recruited from a local college campus the relationships between IRSA 229 
(measured by the IGF-IR KIRA assay) and life style factors were studied, IRSA was negatively associated 230 
with age, body fat percentage and habitual alcohol intake and positively associated with estradiol, 231 
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progesterone and selenium intake [47]. In multivariate analysis only 61% of the variation in IRSA could 232 
be attributed to circulating concentrations of immunoreactive total and free IGF-I and IGFBP-1, IGFBP-2 233 
and IGFBP-3 [47].  It was concluded that further research is needed to better understand the biological 234 
mechanisms responsible and the consequences for the reported associations [47]. 235 
 236 
5.3 IRSA and Exercise 237 
In healthy men circulating concentrations of IRSA (measured by the IGF-IR KIRA assay), and 238 
immunoreactive free IGF-I, total IGF-I and total IGF-II did not change after single 30 seconds sprints, 239 
despite an increase in GH concentrations [74]. Thus, a short sprint exercise may stimulate GH secretion 240 
but does not change IRSA nor IGF concentrations [74].                                                                                                                                                    241 
During a submaximal exercise (45 minutes of cycle ergometer at the lactate threshold) GH 242 
administration to adults with GH deficiency (GHD) induced minor changes in IGFBP-1, IGFBP-2 and 243 
IGFBP-3 without affecting IRSA, IGF-I, IGF-II or IGFBP-3 proteolysis [46]. Thus administration of GH to 244 
adults with GHD did not result in changes of IRSA during submaximal exercise [46].                                                                                   245 
After 8 weeks of resistance, aerobic and combined exercise training both circulating IRSA and immuno-246 
reactive IGF-I remained stable in young healthy women despite a significant improvement in aerobic 247 
fitness, lean mass and upper and lower body strength [57].                                                                                        248 
Taken together, all these findings suggest no significant changes of circulating IRSA during acute and 249 
chronic exercise. However, these observations, should not be interpreted that IRSA lacks importance or 250 
relevance in exercise.  Although that local IGF-I activity I has been  found consistently  upregulated with 251 
both acute and chronic exercises,  at presence, the precise and relative role of systemic versus locally 252 
produced IGF-I  and physical activity is still not clear [58].  Thus in future research samples in the body‘s 253 
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various compartments (blood, interstitial fluid, muscle) should be collected to measure IRSA during a 254 
variety of acute and chronic conditions of exercise. 255 
 256 
5.4 Effects of Insulin on IRSA 257 
During a hyperinsulinemic euglycemic clamp circulating IRSA (measured by the IGF-IR KIRA assay) 258 
acutely decreased both in controls and subjects with impaired glucose tolerance, whereas 259 
simultaneously no changes in immunoreactive total IGF-I or IGF-II were observed [1]. Similarly, IGFBP-1 260 
concentrations significantly decreased in both groups, whereas no changes were seen in IGFBP-3, while 261 
GH and IGFBP-2 levels significantly increased [1].  The acute insulin-induced reduction of IRSA during the 262 
clamp occurred despite  reduction in IGFBP-1 concentrations, and therefore  reduction of IRSA during 263 
the clamp was explained by the concomitant increase of circulating IGFBP-2 concentrations, while the 264 
observed increase in GH concentrations during the clamp most likely were due to decreased negative 265 
feedback of circulating IRSA [1].                                                                                                                                                                            266 
In contrast to the observed acute insulin-mediated decrease of IRSA, chronic hyperinsulinemia did not 267 
reduce circulating IRSA, which was explained by the reduction of both IGFBP-1 and IGFBP-2 268 
concentrations during long-term exposure to high insulin levels [1].  269 
 270 
5.5 Effects of Glucagon on IRSA 271 
Intramuscular glucagon administration to lean subjects, obese subjects and patients with type 1 272 
diabetes mellitus decreased circulating IRSA (measured by the IGF-IR KIRA assay) in all three groups 273 
despite no changes were observed in circulating immunoreactive total IGF-I and IGFBP-3 concentrations 274 
[68]. Since the reduction in IRSA occurred before the glucagon-induced surge in GH, decreased negative 275 
12 
 
feedback by IRSA provides a mechanism for the known increase in GH secretion after administration of 276 
glucagon [68].  The authors hypothesized that the decrease in IRSA after glucagon administration was 277 
related to an increase in circulating IGFBP-1 and IGFBP-2 concentrations which, in turn, most likely was 278 
mediated via a glucagon-mediated activation of the FOXO/mTOR pathway [68]. 279 
 280 
5.6 Effects of GLP-1 on IRSA 281 
Short-term infusions of glucagon-like peptide-1 (GLP-1) in healthy subjects tended to increase IRSA 282 
(measured by the IGF-IR KIRA assay) and reduced IGFBP-1 concentrations [72]. Therefore it was 283 
suggested that IRSA in this study increased secondary to suppression of IGFBP-1 concentrations [72]. 284 
 285 
5.7 IRSA in Serum vs. Interstitial Fluid 286 
With the suction blister technique IRSA (measured by the IGF-IR KIRA assay) was 41 % higher in 287 
interstitial fluid than IRSA in serum [24]. It was suggested that this was related to an increased 288 
enzymatic IGFBP-proteolysis and an altered composition of IGFBPs in interstitial fluid. As a consequence 289 
larger fractions of IGF-I and IGF-II were free to bind to the IGF-IR [24]. In contrast, immuno-reactive total 290 
IGF-I and IGF-II concentrations and IGF-binding proteins (IGFBPs) concentrations were approximately 291 
50% lower in interstitial fluid than in serum [24]. Thus this study suggested that IRSA may be higher at 292 
the tissue level than in the circulation.        293 
 294 
5.8 Effects of Prednisolone on IRSA 295 
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Prednisolone treatment (5mg per day during 1 week) to children with severe asthma significantly 296 
reduced IRSA (measured by the IGF-IR KIRA assay) by 12%  compared to placebo, while no changes were 297 
observed for immunoreactive total IGF-I,  free IGF-I, IGFBP-3, IGFBP-2 IGFBP-1 and IGFBP-1-bound IGF-I 298 
[30]. Prednisolone had no direct effects on IGF-IR phosphorylation. It was concluded that treatment with 299 
glucocorticoids induces a circulating substance that is able to inhibit IGF-IR activation in vitro without 300 
affecting circulating total or free IGF-I [30]. At present the nature of this substance is not identified [30]. 301 
Interestingly, more than twenty years ago existence of a circulating  inhibitor of the IGF-IR  induced by 302 
systemic glucocorticoid treatment was already hypothesized when IRSA was assessed by so called end-303 
point bioassays that measured incorporation of radiolabeled sulfate or thymidine into cultures of 304 
porcine cartilage [53, 80].                                                                                                                                                     305 
In contrast to the findings in the study just discussed, both circulating IRSA and total IGF-I steadily 306 
increased compared to placebo when men received prednisolone in high doses (37.5 mg per day for 5 307 
days) [63]. Although prednisolone increased circulating IRSA above placebo concentrations, this was not 308 
translated into higher levels of IRSA in interstitial fluid (collected by the suction blister technique) [63]. 309 
Thus, short-term prednisolone administration in high doses appears to exert distinct, compartment-310 
specific effects on IRSA. The authors hypothesized that the observed increase in circulating IRSA (and 311 
total IGF-I) after prednisolone was most likely secondary to a prednisolone–mediated increase of insulin 312 
receptor resistance and IGF-IR resistance [63].  Serum obtained from participants after high dose 313 
prednisolone treatment showed reduced ability to  phosphorylate IRS-1, Akt and mTOR in IGF-IR –314 
transfected cells compared to serum after placebo, suggesting that prednisolone treatment in this high 315 
dose induced IGF-IR resistance by impeding post-IGF-IR signaling [63]. These results further support the 316 
hypothesis that glucocorticoids in high doses primarily impair anabolic actions of IGF-I by suppressing 317 
the post-receptor pathways of the IGF-IR rather than by suppressing circulating IRSA [63]. 318 
 319 
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5.9 Effects of Raloxifene and Estrogen on IRSA  320 
While the selective estrogen receptor modulator raloxifene and estrogen suppressed circulating 321 
immunoreactive total IGF-I equally in growth hormone deficiency (GHD) and growth hormone (GH)-322 
replaced hypopituitary women, neither raloxifene nor estrogen affected circulating IRSA (measured  by 323 
the IGF-IR KIRA assay), while  reduction of the total IGF-I: IGFBP-3 ratio, considered by many people as a 324 
proxy for bioavailable IGF-I, was significantly greater during  raloxifene treatment [5]. Treatment with 325 
GH significantly increased IRSA but this effect was attenuated by co-treatment with raloxifene and 326 
estrogen [5]. In addition, proportion of IRSA to total IGF-I was unaffected by any of these treatments [5]. 327 
Since during GH therapy of hypopituitary women co-treatment with raloxifene led to a smaller gain in 328 
lean body mass than GH co-treatment with estrogen, the authors concluded that the observed different 329 
effects on lean body mass between raloxifene and estrogen treatments could not be explained by 330 
differences in IRSA [5]. 331 
 332 
6. IRSA in Disease States 333 
 334 
6.1 IRSA and GHD 335 
Before start of GH treatment IRSA (measured by the IGF-IR KIRA assay) in adult patients with proven 336 
GHD was more frequently below the normal range (<-2 SD)  than immunoreactive total IGF-I 337 
concentrations (81.9 vs. 61.7%, respectively) and this was especially observed in patients older than 40 338 
years of age [88]. After start of GH treatment both IRSA and total IGF-I significantly increased but 339 
changes in IRSA did not parallel changes in total IGF-I [89]. After 12 months of GH treatment total IGF-I 340 
normalized in 81% of patients, whereas in only 50% of patients the IRSA was in the normal reference 341 
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range [89]. In addition, IRSA remained below normal in more than 40% of patients in whom total IGF-I 342 
had normalized [89].  Interestingly, the increase of the IGF-I/IGFBP3 ratio (which has been suggested to 343 
reflect an estimate of bioavailable IGF-I) after 12 months GH treatment was almost similar to the 344 
reported increase of IRSA [89].                                                                                                                                                                                     345 
IRSA was found to be positively related to QOL as assessed by the disease-specific Question on Life 346 
Satisfaction Hypopituitarism (QLS-H) module, whereas total IGF-I was not. These findings suggest that 347 
IRSA may be a more sensitive marker for changes in QOL during GH treatment of adult patients with 348 
GHD [87].  An interesting follow-up study would be to assess the use of IRSA for GH dose titration during 349 
GH treatment of adult patients with GHD.                                                                                                                         350 
Seventy-two hours after administration of a single high dose of the GH receptor blocker pegvisomant to 351 
untreated patients with GHD circulating IRSA (measured by the IGF-IR KIRA assay) significantly 352 
decreased by 14%  and immunoreactive total IGF-I by 23 %  compared to baseline whereas basal GH 353 
levels increased, and IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations did not alter [94]. 354 
Nonetheless, a strong positive correlation between pegvisomant concentrations and circulating IGFBP-1 355 
and IGFBP-2 concentrations was observed, suggesting that the modulatory effects of pegvisomant on 356 
IRSA were mediated in a dose-dependent manner by concomitant increasing concentrations of IGFBP-1 357 
and IGFBP-2  [70, 94].                                                                                                                                                  358 
To our best knowledge to date no data are available whether serum IRSA measured by KIRA assay is also 359 
reduced in subjects with Laron Syndrome. Using a porcine cartilage bioassay it has been found that 360 
serum IRSA in subjects with Laron Syndrome appeared to relate not directly to serum total IGF-I levels, 361 
but to the effects of the various IGFBPs on the bound IGFs  [18]. It was suggested that the regulation and 362 
perhaps also degradation of the IGFBPs play an important role in the regulation an availability of IGF-II in 363 
Laron Syndrome [18].   364 
 365 
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6.2 IRSA and IUGR  366 
Cord blood immunoreactive total IGF-I and total IGF-II, and IRSA (measured by the IGF-IR KIRA assay), 367 
were lower in neonates born with intrauterine growth restriction (IUGR) than in neonates born 368 
appropriate for gestational age (AGA) [79]. IGFBP-1 concentrations were higher in IUGR neonates than 369 
in AGA neonates [79].  As IGFBP-1 is an important regulator of IRSA this may partly explain why levels of 370 
IRSA were suppressed in IUGR neonates:  higher IGFBP-1 concentrations may sequester circulating IGF-I 371 
and thereby reduce IRSA [79]. 372 
 373 
6.3 IRSA and Acromegaly 374 
In a small study of newly diagnosed patients with active acromegaly (based on clinical presentation, 375 
unsuppressed GH levels during an OGTT, and elevated age-matched immune-reactive total IGF-I ) IRSA 376 
(measured by the IGF-IR KIRA assay) was within the reference range in a considerable number of 377 
patients [90]. In this study, the R2 value was 0.70 suggesting that 30% of the variation in IRSA could not 378 
be explained by levels of total IGF-I, demonstrating that IRSA is only partly dependent on total IGF-I [90]. 379 
In addition, the mean percentage of IRSA over total IGF-I was 0.81% in subjects with active acromegaly 380 
indicating that the IGF-IR KIRA assay provided fundamentally different information about the circulating 381 
IGF-I system than IGF immunoassays [90]. Age-adjusted soluble Klotho concentrations were significantly 382 
related to IRSA and it was hypothesized that elevated soluble Klotho levels may directly have reduced 383 
IRSA. Moreover, in this study IRSA was more strongly related to physical measures of QoL than total IGF-384 
I, suggesting that IRSA may better reflect physical limitations perceived in active acromegaly [90].                                                                                                                                                               385 
In an another study among active acromegalics circulating IRSA (measured by the IGF-IR KIRA assay) 386 
decreased significantly during treatment with pegvisomant as well as with combination treatment with a 387 
somatostatin analog and pegvisomant. However, there were no significant differences in the changes of 388 
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IRSA between both treatment regimens [45]. Moreover, immunoreactive total and free IGF-I showed 389 
comparable results as obtained by IRSA [45]. 390 
 391 
6.4 IRSA and PAPP-A2 392 
The metalloproteinase pregnancy-associated plasma protein A2 (PAPP-A2) has been hypothesized to 393 
increase IGF-I bioactivity by specific cleavage of IGFBP-3 and IGFBP-5 [2]. Recently two unrelated 394 
families have been described from whom family members presented with progressive postnatal growth 395 
failure, microcephaly, and thin long bones and decreased bone density [2]. In the blood markedly 396 
elevated circulating concentrations of immunoreactive total IGF-I, IGF-II, IGFBP-3, IGFBP-5 and ALS were 397 
measured. Size-exclusion chromatography showed a significant increase of IGF-I bound in its ternary 398 
complex [19]. Spontaneous GH secretion was also markedly elevated [2]. In both families loss-of-399 
function mutations in the PAPP-A2 gene were found which resulted in one family in severely lowered 400 
and in the other family in undetectable PAPP-A2 activity [19]. When circulating IRSA was measured by 401 
the IGF-IR KIRA assay, IRSA was low and therefore it was hypothesized that low IRSA was responsible for 402 
the observed poor growth [2]. In favor of this latter hypothesis, short-term treatment with recombinant 403 
human IGF-I (rhIGF-I) increased IRSA and this was accompanied by improved growth and height in young 404 
patients with these PAPP-A2 mutations [56]. In addition, during rhIGF-I treatment spontaneous GH 405 
secretion decreased while circulating total IGF-I and IGFBP-3 concentrations remained elevated [56]. The 406 
decline in spontaneous GH secretion most likely resulted from a restored negative feedback as a 407 
consequence of the rise in circulating IRSA after rhIGF-I treatment [56]. 408 
 409 
6.5 IRSA in Turner patients 410 
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To overcome the retarded growth of Turner patients it has been reported that very high doses of GH are 411 
needed [82]. In untreated adult patients with Turner Syndrome IRSA (measured by the IGF-IR KIRA 412 
assay) was found to be decreased [34]. This latter result was found despite the presence of normal 413 
immuno-reactive concentrations of total IGF-I,   IGFBP-1, -2 and -3 and Acid Labile Subunit (ALS) [34]. 414 
However, Western ligand blots of IGFBP-1 and-2, as well as IGFBP-4 in this study population showed 415 
signs of extensive proteolysis while the IGFBP-3 ternary complex was significantly reduced [34]. It 416 
therefore was speculated that the decreased circulating IRSA, may play a role in the reduced action of 417 
GH in Turner syndrome [34]. 418 
 419 
6.6 IRSA and Anorexia Nervosa 420 
In malnourished patients with anorexia nervosa circulating IRSA (measured by the IGF-IR KIRA assay), 421 
total IGF-I (immuno-reactive) and free IGF-I (ultra-filtered) were significantly decreased and IGFBP-1 422 
concentrations were highly increased [76]. During refeeding, a significant increase in circulating IRSA, 423 
total IGF-I and free IGF-I was observed, while BMI also increased [76]. The circulating IRSA and total  IGF-424 
I  showed a correlation coefficient of 0.59  suggesting that in anorexia nervosa patients 60% of variation 425 
in  IRSA could not be explained by concentrations of immunoreactive total IGF-I, thus again 426 
demonstrating that IRSA is only partly dependent on total IGF-I [76].                                                   427 
Measuring PAPP-A and PAPP-A2 activity could be of potential value to understand differences in 428 
circulating IRSA (measured by KIRA assay), total IGF-I and free IGF-I in anorexia nervosa. However to our 429 
knowledge the role of PAPP-A  and the  IGF system in anorexia nervosa  has not yet been studied [75].  430 
 431 
6.7 IRSA and Obesity 432 
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Despite low GH secretion and decreased IGFBP-1, 24h mean circulating IRSA (measured by the IGF-IR 433 
KIRA assay)  was not decreased in obese women [28]. In addition, IRSA did not correlate with BMI and 434 
IGFBP-1 [28]. Therefore it was concluded that these findings argue against elevated IRSA as the 435 
mechanism underlying reduced GH secretion in obesity by an augmented negative feedback.  In another 436 
cross-sectional placebo-controlled study GH administration during 6 months to overweight/obese 437 
women resulted in an increase of both circulating immunoreactive total IGF-I and IRSA (measured by the 438 
IGF-IR KIRA assay) [21]. Interestingly in this latter study the increase in IRSA rather than the increase in 439 
total IGF-I predicted the GH-related increase in lean mass and decrease in total adipose tissue/BMI [21]. 440 
It has been hypothesized that the observed increased ability of media harvested from visceral adipose 441 
tissue (VAT) to activate the IGF-IR in vitro (measured by the KIRA assay) is secondary to an upregulated 442 
PAPP-A mediated release of IGFBP-4 complexed IGF  [35].  However, it is at present unclear whether 443 
local PAPP-A translates into differences of circulating IRSA in human subjects with obesity. 444 
  445 
6.8 IRSA and the Metabolic Syndrome 446 
In a cross-sectional study embedded in a random sample of over 1000 elderly subjects from the 447 
Rotterdam Study, a prospective population-based cohort study,  a progressive rise in circulating IRSA 448 
(measured by the IGF-IR KIRA assay) was found with increasing  insulin resistance as long as fasting 449 
blood glucose levels were within the normal range [11]. However, as soon impaired fasting blood 450 
glucose were present, circulating IRSA peaked and reached a plateau. Finally when blood glucose 451 
concentrations  further increased and individuals  could be classified as having diabetes, circulating IRSA 452 
progressively decreased [11]. In addition, IRSA peaked when three criteria of the metabolic syndrome 453 
were present and then declined significantly when five criteria of the metabolic syndrome were present 454 
suggesting an inverse U-shaped relationship between IRSA and number of components of the metabolic 455 
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syndrome [11]. This latter finding contrasts with previous results reporting an inverse relationship 456 
between the (immunoreactive) total IGF-I/IGFBP-3 ratio and components of the metabolic syndrome 457 
[11, 71]. 458 
  459 
6.9 IRSA and Type 1 Diabetes 460 
Irrespective of pubertal status children and adolescents with type 1 diabetes showed lower IRSA 461 
(measured by the IGF-IR KIRA assay) and immunoreactive total IGF-I, but higher IGFBP-1 than healthy 462 
controls [73].  Suppression of IRSA was relatively more pronounced than total IGF-I and this latter 463 
finding was explained by the more concomitant increase of IGFBP-1 inhibiting IGF-I actions [73].                                                                                                                          464 
When comparing patients with and without residual -cell function IRSA and IGF-II as well as IGFBP-3 465 
were significantly higher in prepubertal patients with residual -cell function, supporting the hypothesis 466 
that the portal supply of insulin to the liver is an important regulator of the activity of the GH-IGF axis, at 467 
least in prepubertal children, since such relation was absent in pubertal patients [73].                                                                                                                                                      468 
Insulin plays an important role in the regulation of the GH-IGF-I axis. When comparing the GH-IGF-I axis 469 
response after a single dose human NPH insulin, insulin detemir and insulin glargine in type 1 diabetes 470 
patients, it was found that independent of the actual plasma glucose concentrations, IRSA (measured by 471 
the IGF-IR KIRA assay) was higher and IGFBP-1 lower after insulin detemir than after NPH insulin and 472 
glargine administration, thereby explaining the lower GH levels [51]. By contrast, immunoreactive total 473 
IGF-I, IGFBP-2 and IGFBP-3 were comparable after administration of these three different insulins [51]. 474 
Since it is thought that the combination of a reduced GH secretion and an increased IRSA may have 475 
beneficial metabolic effects in type 1 diabetes, this study suggested that in this respect insulin detemir 476 
compared to NPH insulin and glargine is superior [51].                                                                                                                    477 
Ma et al. showed in type 1 diabetes patients that IRSA was more sensitive to short-term changes in 478 
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insulin exposure than total IGF-I, although the physiological significance of this observation has to be 479 
determined [52]. In this latter study again a strong inverse relationship between IRSA and circulating 480 
IGFBP-1 levels was found [52]. Moreover, despite distinct glucose-lowering properties, equal doses of 481 
human insulin, insulin aspart and two biphasic aspart preparations (BIAsp50 and BIAspo70) had similar 482 
effects on IRSA [52].                                                                                                                                                     483 
Hedman et al. studying in type 1 diabetes whether the route of insulin administration affected 484 
circulating IRSA (measured by the IGF-IR KIRA assay) found that continuous intraperitoneal insulin 485 
infusion (CIPII) induced higher circulating IRSA, but also higher circulating (immune-reactive) total IGF-I 486 
and IGF-II levels and lower IGFBP-1 than subcutaneous insulin administration [38]. This again supports 487 
the hypothesis that the route if insulin administration is important for the activity of the IGF system [38]. 488 
A low endogenous circulating IRSA is likely to augment the secretion of growth hormone, which may 489 
lead to insulin resistance and finally in an increased risk of late diabetic complications [43]. The observed 490 
higher circulating IRSA after intraperitoneal insulin administration suggests that CIPII treatment in type 1 491 
diabetes patients is better correcting alterations of the IGF system than subcutaneous insulin 492 
administration [38]. 493 
 494 
6.10 IRSA and Type 2 Diabetes                                                                                                                                                                            495 
Varewijck et al. found that IRSA (measured by the IGF-IR KIRA assay) was borderline significantly lower 496 
in patients with type 2 diabetes on metformin than in non-diabetic controls, while immunoreactive total 497 
IGF-I concentrations were significantly lower in patients with type 2 diabetes than in non-diabetic 498 
participants [86]. After 36 weeks of insulin therapy IRSA significantly decreased in patients with type 2 499 
diabetes, while serum total IGF-I concentrations remained unchanged during this period [86]. The 500 
observed decline in IRSA after 36 weeks insulin therapy is in line with a study discussed above, which 501 
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showed that hyperinsulinemia suppressed IRSA, whereas total serum IGF-I did not change [1].  In this 502 
latter study it was concluded that insulin decreased IRSA through differential modulation of IGFBPs: 503 
insulin suppressed IGFBP-4 and IGFBP-1 and increased IGFBP-2 concentrations [1].                                                                                                                                                           504 
Prior to bariatric surgery in severe obese type 2 diabetic patients IRSA (measured by the IGF-IR KIRA 505 
assay) was significantly elevated, while total IGF-I was not increased [12]. After bariatric surgery IRSA 506 
only slightly increased at 3 months and was unchanged at 12 months, while simultaneously there were 507 
no changes in total IGF-I and total IGF-II [12]. In addition, IGFBP-1 significantly increased and IGFBP-3 508 
significantly decreased and these changes continued up to 12 months [12]. The biological importance of 509 
these findings is unclear at the moment. 510 
 511 
6.11 Effects of Intensive Insulin Therapy on IRSA in the Intensive Care 512 
Upon admission at the intensive care unit immunoreactive total IGF-I concentrations and IRSA 513 
(measured by the IGF-IR KIRA assay) were lower and GH concentrations were elevated in critically ill 514 
children compared with a healthy reference population [33].  In this respect there were no differences 515 
between children randomized to conventional insulin therapy (CIT) and to intensive insulin therapy (IIT) 516 
[33]. At day 3 of admission ITT decreased IRSA compared to CIT, while total IGF-I concentrations were 517 
similar when comparing both treatment arms [33]. In addition, compared to CIT, at day 3 of admission 518 
IGFBP-3 and ALS concentrations were decreased and IGFBP-1 concentrations were increased in the IIT 519 
group [33]. According the authors the decreased IRSA in the IIT group may point to aggravated GH 520 
resistance [33]. A second possible explanation for the decreased circulating IRSA may be that the IIT 521 
suppressed endogenous portal insulin levels stronger than CIT and this may have led a to decreased 522 
hepatic IGF-I production, which has resulted in a reduced IRSA [33].  The long-term functional 523 
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consequences of ITT on the changes in the IGF-I system are unclear at present and should be further 524 
investigated. 525 
 526 
6.12 Effects of Insulin on IRSA in Very Low Birth Weight Infants  527 
In a small randomized controlled study intravenous insulin administration to very low birth weight 528 
infants throughout the first week of life improved glucose control and increased IRSA (measured by the 529 
IGF-IR KIRA assay) compared with standard care [4]. There were trends toward faster growth in leg 530 
length and increased weight gain in the infants treated with insulin (and higher IRSA) compared with the 531 
standard care group [4]. During the 7-day study period, there were no significant differences in 532 
circulating (immuno-reactive) total IGF-I levels between the infants treated with insulin and those 533 
receiving standard care [4]. Therefore it was concluded that early insulin therapy increased IRSA and 534 
improved blood glucose control and this could be contributing to less morbidity among very low birth 535 
weight infants [4]. 536 
 537 
6.13 IRSA and Cushing Disease 538 
Untreated Cushing disease was characterized by normal circulating IRSA (measured by the IGF-IR KIRA 539 
assay)  and immunoreactive total IGF-I concentrations [83]. Treatment of patients with an active Cushing 540 
Disease with a low dose of the somatostatin analog pasireotide (which binds with high affinity to 541 
somatostatin receptors subtypes 1-3 and 5) during 28 days reduced cortisol production and normalized 542 
urinary free cortisol in 29% [83]. During treatment of pasireotide  Z-scores for IRSA and total IGF-I 543 
decreased significantly to values < -2 SD in 43% and 35%, respectively, suggesting the induction of 544 
growth hormone deficiency de novo [83].     545 
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 546 
6.14 IRSA and Graves Ophthalmopathy 547 
In subjects diagnosed with Graves Ophthalmopathy values for IRSA (measured by the IGF-IR KIRA assay) 548 
were found to be low normal (Z-score: -1.5 SD ± 0.1 SD) whereas immunoreactive total IGF-I was normal 549 
(Z-score: 0.6 ± 0.2 SD) [84]. In line with these findings it was reported more than twenty years ago that 550 
IRSA was markedly reduced in thyrotoxicosis when IRSA was assessed by measuring incorporation of 551 
radiolabeled sulfate into cultures of porcine cartilage [54].                                                                                   552 
 553 
6.15 IRSA and Kidney Disease 554 
Patients with end-stage renal disease showed elevated GH, high normal circulating immunoreactive 555 
total IGF-I and subnormal IRSA (measured by the  IGF-IR KIRA assay) compared to controls [29]. After 7 556 
days treatment with recombinant GH IRSA tended to be lower in patients with end-stage renal disease 557 
than controls while total IGF-I increased to the same extent as controls [29]. The authors suggested that 558 
the observed changes in IRSA (but not in total IGF-I) indicated that hepatic sensitivity to GH was reduced 559 
by 50 % in patients with end-stage renal disease and that in patients with end-stage renal disease 560 
changes in total IGF-I during treatment with GH are not reflecting changes in endogenous activity of IGF-561 
I [29].                                                                                                                                                                                     562 
In another study Ivarsen et al. found that directly after hemodialysis there were marked reductions in 563 
IRSA (measured by the IGF-IR KIRA)  and ultrafiltered free IGF-I in non-diabetic patients with end-stage 564 
renal disease while there were only marginal reductions in immunoreactive total IGF-I and total IGF–II 565 
[40]. They hypothesized that the decrease in IRSA was a consequence of an increase in IGFBP-1, 566 
sequestering free IGF-I, and thereby reducing IRSA [40]. In accordance with this view the increase in 567 
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IGFBP-1 was accompanied by a parallel increased complex formation between IGF-I and IGFBP-1 [40]. In 568 
addition, Ivarsen et al. suggested that catabolism induced by hemodialysis may be (in part) reflected by 569 
the observed reductions in IRSA [40].  When a meal was served to patients on maintenance 570 
hemodialysis before hemodialysis,  this resulted in a 20% maximum increase of IRSA at 120 min during 571 
hemodialysis, whereas total IGF-I  concentrations showed a maximum increase of 5% at 180 min [64].                                                                                                                                                                                          572 
In another study by the same group, a baseline meal was offered at the day of hemodialysis [65]. In this 573 
latter study the expected postprandial increase in IRSA after a baseline meal was absent on all four 574 
study days. IRSA only increased above baseline when a second meal was offered at the day of 575 
hemodialysis [65]. In addition, immunoreactive total IGF-I did not significantly change and remained 576 
fairly constant on all four study days [65]. The increase in IRSA after the second meal on the day of 577 
hemodialysis suggested a beneficial effect of frequent meals for patients on maintenance hemodialysis 578 
[65].                                                                                                                                                                                       579 
Brugts et al. studied patients with end stage renal disease treated on continuous ambulatory peritoneal 580 
dialysis (CAPD) and found that circulating IRSA (measured by the IGF-IR KIRA assay) increased both after 581 
administration of a dialysate with a mixture of amino acids plus glucose or a dialysate that contained 582 
only glucose while no changes in circulating immunoreactive total IGF-I concentrations were observed 583 
(Figure 5) [9]. Therefore they concluded that circulating IRSA rather than total IGF-I is involved in acute 584 
responses to nutritional interventions in patients with end stage renal disease treated on CAPD [9].                   585 
                                                                                                            586 
6.16 IRSA and Liver Cirrhosis  587 
Circulating IRSA (measured by the IGF-IR KIRA assay), immunoreactive total IGF-I and total IGF-II were 588 
reduced in patients with alcoholic liver cirrhosis compared to controls, whereas IGFBP-1, IGFBP-2 and 589 
the soluble IGF-II receptor were elevated [44].  Interestingly, the IRSA was fourfold elevated in ascites as 590 
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compared with serum while in contrast, all other IGF-I-related peptides but pro-IGF-II in ascites were 591 
reduced as compared with serum [44]. Thus this study suggested that in contrast to immunoreactive 592 
total IGF-I concentrations, IRSA can be higher in fluids from an extravascular compartment than in 593 
serum. However, the pathophysiological significance of these findings remains to be clarified [44].                                                                                                                              594 
In another study circulating IRSA (measured by the IGF-IR KIRA assay) significantly decreased in patients 595 
with liver cirrhosis after an oral glucose tolerance test (OGTT) and the same tendency was observed in 596 
healthy subjects [15]. This reduction of IRSA in patients with liver cirrhosis occurred despite unchanged 597 
concentrations of (immunoreactive) total IGF-I and free IGF-I [15]. It was hypothesized that the 598 
reduction of IRSA in patients with liver cirrhosis during an OGTT was related to higher concentrations of 599 
IGFBP-1 and a faster disappearance of IGFBP-1 bound IGF-I [15].                                                                                                                                                   600 
Treatment of patients with liver cirrhosis with a transjugular intrahepatic porto-systemic shunt (TIPS) 601 
may induce anabolism [39].  Holland-Fischer et al. found that the body cell mass of patients with liver 602 
cirrhosis increased after TIPS [39]. However, circulating concentrations of IRSA (measured by the IGF-IR 603 
KIRA assay), immunoreactive total IGF-I, total IGF-II and IGF-binding proteins did not change, suggesting 604 
that other mechanisms than activity of the IGF system are involved in the anabolic effects of TIPS [39].    605 
 606 
6.17 IRSA and Hepatocellular Carcinoma (HCC) 607 
Circulating IRSA (measured by the IGF-IR KIRA assay) in patients with hepatocellular carcinoma was 608 
twice as high as found in patients with liver cirrhosis [23]. However, IRSA concentrations in both groups 609 
were markedly below the concentrations observed for healthy controls [23]. Similar patterns as found 610 
for circulating IRSA were observed for circulating immunoreactive total IGF-I, IGF-II and IGFBP-3 whereas 611 
pro-IGF-II and the IGF-I to IGFBP-3 ratio showed less pronounced but nevertheless significant differences 612 
[23]. Changes in tumor burden after treatment did not affect IRSA or IGF-II [23].  It was concluded that 613 
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the observed differences in parameters of the IGF system between patients with hepatocellular 614 
carcinoma, liver cirrhosis and healthy subjects were mainly explained by variations in liver status [23]. 615 
Therefore the authors questioned the clinical utility of measuring circulating IGF variables as markers of 616 
hepatocellular carcinoma [23].   617 
 618 
6.18 IRSA, Lung Cancer and Pleural Fluid 619 
When IRSA (measured by the IGF-IR KIRA assay) and other members of the IGF family were compared in 620 
pleural fluid and in blood from patients with lung cancer and nonmalignant lung disease, it was found 621 
that IRSA was threefold higher in pleural fluid than in corresponding serum samples, regardless of 622 
etiology [25]. In contrast immunoreactive total IGF-I concentrations did not differ between blood and 623 
pleural fluid [25]. In addition, PAPP-A, an IGFBP protease that may cleave IGFBP-4 and IGFBP-5 [49, 59, 624 
60], was elevated in pleural fluid and it was speculated by the authors that IGFBP-proteases (inclusive 625 
PAPP-A) were involved in the observed increase of IRSA in pleural fluid [25]. This study suggested that 626 
local factors at the tissue level may have major effects on IRSA and that local IRSA may substantially 627 
differ from that measured in the circulation [25].  628 
 629 
6.19 IRSA, Ovarian Carcinoma and Ascites 630 
As discussed above, PAPP-A may stimulate IGF-I action through proteolysis of IGFBP-4 and in 631 
experimental animal models it has been found that PAPP-A may accelerate ovarian tumor growth by 632 
releasing IGF-I [78].  IRSA (measured by the IGF-IR KIRA assay) in ascites of patients with ovarian cancer 633 
was 31% higher than in serum [78]. In contrast, concentrations of immunoreactive total IGF-I were 634 
similar in serum and ascites, while levels of IGF-II and IGFBP-3 were decreased in ascites compared to 635 
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serum [78]. Since it was found that ascites contained a 46-fold higher concentrations of PAPP-A than 636 
serum and also IGFBP-4, it was hypothesized that PAPP-A in ascites may function to increase IGF-I 637 
actions [78]. In favor of this latter possibility it was found that ascites contained less intact IGFBP-4 than 638 
plasma and higher concentrations of proteolytically cleaved IGFBP-4 than intact IGFBP-4 [78]. 639 
 640 
6.20 IRSA and Dementia 641 
Within the Rotterdam Study higher levels of circulating IRSA (measured by the IGF-IR KIRA assay) were 642 
associated with a higher prevalence and a higher incidence of dementia suggesting that IRSA increases 643 
in response to neuropathological changes that occur in dementia [20]. Similar associations were found 644 
for Alzheimer's disease and in persons without diabetes mellitus [20]. Unfortunately in this latter study 645 
no circulating immunoreactive total IGF-I concentrations were measured. As a consequence it was 646 
impossible to compare whether in this respect there existed discrepancies between IRSA and total IGF-I. 647 
Interestingly, we found in another study evidence of an interaction between ApoE-ε4 and tertiles of 648 
IRSA [32].  IRSA in the median and top tertiles was related to increased dementia incidence in hetero- 649 
and homozygotes of the ApoE-ε4 allele, but did not show any association with dementia risk in people 650 
without the ApoE-ε4 allele shedding a new light on the association between IGF-I signaling and the 651 
neuropathology of dementia [32].  652 
 653 
6.21 IRSA and Longevity 654 
IRSA as measured by the IGF-IR KIRA assay, immunoreactive total IGF-I and the IGF-I/IGFBP-3 ratio were 655 
all three significantly lower in centenarians' offspring compared to offspring matched-controls [92]. In 656 
addition, IRSA in centenarians' offspring was inversely related to insulin sensitivity [92]. Interestingly, it 657 
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was further found that in contrast to circulating total IGF-I concentrations, mean IRSA was comparable 658 
between centenarians and their offspring [92].  However, further studies are needed to understand the 659 
precise role of IRSA  in the modulation of the human aging process [92].                                                                660 
We also measured IRSA by KIRA assay  in centenarians and found relatively low IRSA [92]. Mean IRSA in 661 
106 centenarians was 132 (107-157) pmol/L (mean (25th-75th percentile)), while mean IRSA in 192 662 
centenarians’ offspring and 80 offspring matched controls were 144 (119-170) pmol/L and 161 (134-663 
187) pmol/L [92]. In addition, centenarians showed a 2-fold higher insulin sensitivity than centenarians’ 664 
offspring  [92]. Therefore we hypothesized that, despite low circulating IRSA, the post-receptor signaling 665 
pathways of the IGF-IR were up-regulated in centenarians [92].  666 
 667 
6.22 IRSA and Mortality 668 
In a prospective observational of more than 400 healthy elderly men (aged 73-94 yrs.) IRSA (measured 669 
by the IGF-IR KIRA assay) accounted for 2.5 % (range 0.2-5.9%) of circulating (immunoreactive) total IGF-670 
I concentrations whereas free IGF-I (measured by immunoassay) accounted for 0.7% [10]. These findings 671 
suggested that IRSA was most likely reflecting stimulation of the IGF-IR by free IGF-I and free IGF-II and 672 
IGFs dissociated from the IGFBPs during incubation of serum samples [10]. Survival of these elderly men 673 
in the highest quartile of IRSA was significantly better than in the lowest quartile, both in the total study 674 
group (Figure 6) as well as in subgroups having a medical history of cardiovascular disease or a high 675 
inflammatory risk profile [10]. Such relationships were not observed for immunoreactive total or free 676 
IGF-I [10]. Thus this study suggested that a relatively high circulating IRSA in elderly men of 73-94 yrs. 677 
may be associated with extended survival and with reduced cardiovascular risk [10].  678 
 679 
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7. Discussion and conclusions 680 
The main reason for using immunoassays as an estimate of circulating IGF-I bioactivity has long been the 681 
lack of reliable IGF-I bioassays  [66].  The measurement of IRSA by the IGF-IR KIRA assay has opened a 682 
completely new era and is a novel tool to asses circulating IGF-I bioactivity under conditions that mimic 683 
the in vivo cellular environment as good as possible. In this review many studies are discussed showing 684 
that measuring IRSA often produces other information in detecting changes of the IGF system than the 685 
commonly used IGF-I immunoassays. In contrast to IGF-I immunoassays the IGF-IR KIRA assay is sensitive 686 
for modifications of IGF-IR activation by circulating IGFBPs and IGFBP-proteases [14, 48].                             687 
This review shows that in many conditions in health and disease results for IRSA (measured by the IGF-IR 688 
KIRA assay) and circulating total immunoreactive IGF-I concentrations  (measured by immunoassays) are 689 
discordant (Table 1) . These discrepancies are probably directly related to fundamental differences that 690 
exists between both methods. With the IGF-IR KIRA assay all serum factors, which directly or indirectly 691 
may phosphorylate tyrosine residues of the IGF-IR, become detectable. Moreover, the IGF-IR KIRA assay 692 
is sensitive to modulating effects of the IGFBPs on the interactions between IGF-I and the IGF-IR [14]. 693 
Thus the IGF-IR KIRA assay may give information about net overall effects of IGF-I, IGF-II, IGFBPs and 694 
IGFBP-proteases on IGF-IR activation. In contrast, levels of immunoreactive total IGF-I are mainly 695 
determined by IGF-I bound to the IGFBPs. However, it is unclear which part  of this  latter fraction  is 696 
involved in the activation of the IGF-IR since as discussed above, only IGF-I in the free state is able to 697 
stimulate directly the IGF-IR [42]. Thus  discrepancies between  IRSA (measured by the IGF-IR KIRA assay) 698 
and circulating total immunoreactive IGF-I concentrations  (as measured by immunoassays) could be  699 
due to stimulating effects of biological factors on the IGF-IR that may be detected by the IGF-IR KIRA 700 
assay but  are not recognized by total IGF-I immunoassays. Moreover, antibodies in IGF-I immunoassays 701 
may also recognize IGF-I molecules or fragments that are biologically inactive and unable to stimulate 702 
the IGF-IR.  Therefore Zapf et al. previously suggested that results obtained by IGF-I immunoassays 703 
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should always be confirmed by IGF bioassays before conclusive statements of measured IGF-I levels on 704 
physiological or pathophysiological issues are made (87).                                                                                                                        705 
This review suggests that measurement of circulating IRSA (by the IGF-IR KIRA assay) is especially 706 
superior to immunoreactive total IGF-I to monitor therapeutic interventions. Although the IRSA being 707 
measured by the IGF-IR KIRA assay probably more closely reflects true bioactive IGF-I than the 708 
measurement of total IGF-I in serum by immunoassays, it is good to realize that that the IGF-IR KIRA 709 
assay does not capture all the post-receptor intracellular events mediated by the IGF-IR. The IGF-IR KIRA 710 
assay only quantifies IGF-IR phosphorylation of tyrosine residues. Nevertheless, it has been found that 711 
the IGF-IR KIRA assay shows  excellent correlations with the more classical endpoint bioassays [66]. Thus 712 
the IGF-IR KIRA assay in its present version does not provide information about the further intracellular 713 
propagation and IGF-IR–mediated signal more downstream [14, 66].  On the other hand, this may be a 714 
strength of the IGF-IR KIRA assay: in so called-endpoint bioassays it is often impossible to disentangle 715 
the relative contribution of IGF-IR mediated effects to a certain end result since there is extensive cross-716 
talk at the post-receptor level between different intracellular signaling networks which are activated by 717 
other ligands than IGF-I [77]. Moreover, many biological responses are complex and depend often on a 718 
cascade of cross-talk and post-receptor events and stimulation of the IGF-IR may activate different 719 
signaling pathways intracellularly upon receptor binding in a concentration-dependent manner (Figure 720 
2).                                                                                                                                                                                  721 
Although the signal measured by the IGF-IR KIRA assay is readily direct and specific, the IGF-IR has up to 722 
6 key tyrosine residues of which of some the role in vivo is not yet fully clear [85]. In addition, the 723 
antibody used to capture the tyrosine residues may not well recognize all residues equally well because 724 
of dependence of affinity on flanking sequence and proximity of other sites [85]. Thus the IGF-IR KIRA 725 
bioassay only provides a crude, albeit convenient, measure of kinase activation.                                                                                                          726 
Interestingly,  as discussed above, IRSA in samples from the interstitial fluid obtained by the suction 727 
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blister method was almost 50% higher than in matched serum samples [24]. Moreover, IRSA was higher 728 
in ascites than in serum in patients with liver cirrhosis and in patients with ovarian cancer [15, 44]. In 729 
addition, IRSA was also higher in pleural fluid than in serum in patients with lung disease [25, 78]. Thus 730 
the amount of IRSA present in interstitial fluid and the extravascular tissues may not only substantially 731 
differ from that measured in the circulation but that the amount of local IRSA seems not directly related 732 
to circulating IRSA. These findings suggest that it is necessary to collect information about both the 733 
paracrine (local) and endocrine (circulating) IRSA to obtain an overall impression of the role of the IGF 734 
system in health and disease.                                                                                                                                           735 
An important limitation of the IGF-IR KIRA assay in its present form is that it is more labor intensive and 736 
more expensive than total IGF-I immunoassays. It measures only the amount of IGF-I (and other ligands) 737 
that that can interact with the IGF-I receptor and activate its tyrosine kinases during a short time of 738 
incubation (15 minutes). For the future the IGF-IR KIRA assay should be further miniaturized and 739 
automated to run many samples in a relatively short time. In addition, there should be a single 740 
universally accepted standard for the IGF-IR KIRA assay for calibration and large pools of reference 741 
serum samples should become available to monitor the (dis)concordance in results between different 742 
laboratories using an IGF-IR KIRA assay.                                                                                                                         743 
Easy access and reliability of a cell line transfected with the human IGF-IR are prerequisites to 744 
implement wide-spread use of the KIRA assay. Cells transfected with the human IGF-IR frozen in 745 
microwell plates offer a potential valid alternative to fresh cells from a growing culture. When these 746 
plates can be used immediately after thawing and the frozen cells can be revitalized without passaging 747 
and washing cells, total time needed to perform the assay is considerably shortened. This strategy may 748 
further help to overcome an important bottleneck to implement wide-spread use of the KIRA assay; it 749 
removes day-to-day variation, eliminates passage effects and improves consistency of cell-based assay 750 
results. The production of these frozen cells should be standardized so that different batches are highly 751 
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comparable. Freezing and resuscitation protocols should be optimized, and the performance of these 752 
ready-to-use cells should be compared with those from continuous culture to determine whether they 753 
could be used as a replacement.  To further reduce costs and consistency of the KIRA the antibodies 754 
should be replaced by aptamers.                                                                                                                                                                                    755 
In conclusion, the IGF-IR KIRA assay is a novel tool that has opened a new era. When studying  changes 756 
of the GH-IGF-I axis in health and disease the IGF-IR KIRA assay provides in many conditions different 757 
information about the IGF system than the commonly used total IGF-I immunoassays. The IGF-IR KIRA 758 
assay probably more closely reflects true bioactive IGF-I compared to measurements of total IGF-I in 759 
serum by immunoassays. In health and disease IRSA measured by the IGF-IR KIRA assay was 760 
considerably higher in samples from interstitial fluid and ascites than in serum, suggesting that both 761 
local and circulating IRSA should be measured in order to get a more complete view of the role of the 762 
IGF system.  763 
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Legends 1107 
Figure 1.  1108 
Schematic overview of the IGF system. The IGF system is composed of two Insulin-like Growth Factors  1109 
IGF-I (yellow)  and IGF-II (blue), six high affinity Insulin-like Growth Factor Binding Proteins (IGFBP-1 to -1110 
6), several related IGFBPs (IGFBPrp), IGFBP proteases and two receptors; the IGF-I receptor (IGF-IR) and 1111 
the IGF-II receptor. All IGFBPs can bind both IGF-I and IGF-II (however with different binding affinity for 1112 
some). Only the unbound forms of IGFs are thought to interact with the IGF-IR and the IGF-II receptor. 1113 
The IGF-IR can bind IGF-I with high affinity but also IGF-II with 10-fold lower affinity. In the Figure also 1114 
insulin (red) and the insulin receptor (IR) are shown. As IGFs and insulin as well as the IGF-IR and the IR 1115 
share high sequence homology they are able to bind and activate each other’s cognate receptors but 1116 
with considerably lower avidity (displayed by the differences in thickness of the arrows). Interestingly, in 1117 
the body the IGF-I and IR may form hybrids which are preferentially activated by IGF-I. 1118 
 1119 
Figure 2  1120 
Model of the IGF-IR signaling pathway. Binding of IGF-I (or IGF-II) to the IGF-IR results in auto 1121 
phosphorylation of tyrosine residues located within the intracellular kinase domain of the IGF-IR, being 1122 
the first step in the intracellular signaling cascade. This starts the activation of multiple complex 1123 
intracellular pathways (including the RAS-ERK-MAPK pathway and the PI3K/AKT pathway) and results in 1124 
multiple biological effects in a variety of tissues and cells in the body. 1125 
 1126 
Figure 3 1127 
Schematic overview of procedures the IGF-I Kinase Receptor Activation Assay (IGF-IR KIRA).The time to 1128 
perform the assay is 4-days. On day 1 human embryonic kidney (EBNA) cells stabile transfected with the 1129 
human IGF-IR are cultured in 48 well culture plates (200,000 cells per well) in medium containing 10% 1130 
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fetal calf serum (FCS). On day 2 the medium is replaced by medium containing 0.1% human serum 1131 
albumin (HSA). A second 96 well plate is coated with a human IGF-IR capture antibody.  On day 3 cells 1132 
are stimulated with serum for 15 minutes and then cells are lysed. Lysate is transferred to the washed 1133 
96 well plate that was coated with the human IGF-IR capture antibody on day 2. On day 4 the 96 well 1134 
plate is washed and a second antibody is added, which specifically recognizes phosphorylated residues 1135 
located at the kinase domains of the IGF-IR. This latter antibody contains a europium (EUR) label so that 1136 
phosphorylation of the tyrosine residues of IGF-I receptor can be quantified in a time-resolved 1137 
fluorometer. 1138 
 1139 
Figure 4. Age distribution of serum total IGF-I levels (upper panel) and IRSA (lower panel) in 94 patients 1140 
diagnosed with growth hormone deficiency (GHD) (black dots). The shaded area depicts the 95% 1141 
confidence interval in normal subjects per decade of age. IRSA in adult patients with proven GHD was 1142 
more frequently below the normal range (<-2 SD) than total IGF-I concentrations.  From: IGF-I Bioactivity 1143 
Better Reflects Growth Hormone Deficiency than Total IGF-I. J Clin Endocrinol Metab. 2011; 96(7):2248-1144 
2254. doi:10.1210/jc.2011-0051.  J Clin Endocrinol Metab | Copyright © 2011 by The Endocrine Society. 1145 
 1146 
Figure 5  1147 
Top: Changes in circulating total (immunoreactive) IGF-I concentrations in the fed state after a dialysate 1148 
that only contained glucose (G) and after a dialysate containing aminoacids and glucose (AA and G), 1149 
respectively (basal state = 100%). Bottom: Changes in circulating IRSA in the fed state compared to 1150 
baseline after G and after AA and G dialysate, respectively (basal state = 100%). Circulating IRSA 1151 
increased both after administration of a dialysate with a mixture of amino acids plus glucose or a 1152 
dialysate that contained only glucose while no changes in circulating total (immunoreactive) IGF-I 1153 
43 
 
concentrations were observed. From: Bioactive rather than total IGF-I is involved in acute responses to 1154 
nutritional interventions in CAPD patients Nephrol Dial Transplant. 2009; 25(3):940-946. 1155 
doi:10.1093/ndt/gfp576.Nephrol Dial Transplant | © The Author 2009. Published by Oxford University 1156 
Press on behalf of ERA-EDTA. 1157 
 1158 
Figure 6 1159 
Cox proportional hazard plots (percent) showing Cumulative Survival for groups of circulating 1160 
(immunoreactive) total IGF-I concentrations (A), circulating (immunoreactive) free IGF-I concentrations 1161 
(B) and IRSA concentrations as measured by the IGF-IR KIRA assay(C). P for trend reached statistical 1162 
significance only in the IRSA group as measured by the IGF-IR KIRA assay. Groups of IRSA are shown as 1163 
follows: group 1 (—), ≤25th percentile; group 2–3 (– – –), between 25th and 75th percentile; and group 1164 
4 (—•—), ≥75th percentile. Trends across IGF-I bioactivity risk groups were based on Cox proportional 1165 
hazard models with linear effect of the risk factor (Armitage trend test). Maximum time of follow-up was 1166 
103 months. See also text. From: Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men 1167 
Is Associated with Increased Mortality. J Clin Endocrinol Metab. 2008; 93(7):2515-2522. 1168 
doi:10.1210/jc.2007-1633.  J Clin Endocrinol Metab | Copyright © 2008 by The Endocrine Society. 1169 
 1170 
 1171 
Table 1. Overview of reported discordant results   of  circulating  IRSA  and immunoreactive Total IGF-I  
concentrations in Health (A) and Disease States (B)  (see text for details) 
 
A] In Health 
 IRSA Immunoreactive 
Total IGF-I 
Reference 
    
Fasting ↓ ≈ 25 
    
During a 
hyperinsulinemic  
euglycemic clamp 
↓ ≈ 31 
    
During administration 
of glucagon 
↓ ≈ 32 
    
After short-term 
administration of 5 mg 
Prednisolone/day  
↓ ≈ 35 
    
After administration of 
raloxifene 
≈ ↓ 39 
    
After administration of 
estrogen 
≈ ↓ 39 
    
 
 
 
 
 
 
 
 
 
 
Table 1
B] In Disease States    
 IRSA Immunoreactive 
Total IGF-I 
Reference 
    
Untreated GH 
deficiency 
↓↓ ↓ 40 
    
During GH therapy of 
adult GH deficiency  
↑ ↑↑ 41 
    
Untreated active 
Acromegaly  
↑ ↑↑ 46 
    
PAPP-A2 mutation ↓ ↑↑ 48, 49 
    
Untreated Turner 
Syndrome 
↓ ≈ 52 
    
Type 1 diabetes ↓↓ ↓ 58 
    
Untreated  Type 2 
Diabetes 
≈↓ ↓↓ 63 
    
Insulin-treated Type 2 
diabetes 
↓ ≈ 63 
    
Severe obesity and Type 
2 diabetes 
↑ ≈ 64 
    
Intensive vs. 
Conventional insulin 
therapy on the IC 
↓ ≈ 65 
    
Insulin therapy to Very 
Low Birth Weight 
infants 
↑ ≈ 66 
    
Graves 
Ophthalmopathy 
↓ ≈ 68 
    
Endstage Renal Disease 
after hemodialysis 
↓↓ ≈↓ 70, 71 
    
Endstage Renal Disease 
after administration of 
dialysate  
↑ ≈ 74 
  
↓  Decreased 
≈   Unchanged  
↑  Increased 
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Abstract 27 
Determination of true IGF-I bioactivity in serum and other biological fluids is still a  substantial challenge. 28 
The IGF-IR Kinase Receptor Activation assay (IGF-IR KIRA assay) is a novel tool to asses IGF-IR stimulating 29 
activity (IRSA) and has opened a new era in studying the IGF system. In this paper we discuss many 30 
studies showing that measuring IRSA by the IGF-IR KIRA assay often provides fundamentally different 31 
information about the IGF system than the commonly used total IGF-I immunoassays. With the IGF-IR 32 
KIRA assay phosphorylation of tyrosine residues of the IGF-IR is used as read out to quantify IRSA in 33 
unknown (serum) samples. The IGF-IR KIRA assay gives information about net overall effects of 34 
circulating IGF-I, IGF-II, IGFBPs and IGFBP-proteases on IGF-IR activation and seems especially  superior 35 
to immunoreactive  total IGF-I  in monitoring therapeutic interventions. Although the IRSA as measured 36 
by the IGF-IR KIRA assay probably more closely reflects true bioactive IGF-I than  measurements of total 37 
IGF-I in serum, the IGF-IR KIRA assay in its current form does not give information about all the post-38 
receptor intracellular events mediated by the IGF-IR. Interestingly, in several conditions in health and 39 
disease IRSA measured by the IGF-IR KIRA assay is considerably higher in interstitial fluid and ascites 40 
than in serum. This suggests that  both the paracrine (local) and endocrine (circulating) IRSA should be 41 
measured to get a complete picture  about  the role of the IGF system in health and disease. 42 
 43 
Keywords: IGF-I, IGF-I receptor, IGF-I Bioactivity, KIRA, Immunoassays, Endocrine, Paracrine, Health, 44 
Disease 45 
 46 
 47 
 48 
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1.Introduction 94 
Insulin-like growth factor-I (IGF-I) is tightly bound by six high affinity IGF binding proteins (IGFBP-1-6) in 95 
the circulation. In healthy subjects, approximately 95% of all circulating total IGF-I is present as a ternary 96 
complex formed by IGF-I, IGFBP-3 and acid labile subunit (ALS), making this complex quantitatively the 97 
most important, while the remaining IGF-I circulates in a free form (<1%) or as binary complexes 98 
(approximately 4–5%) [16]. It is assumed that free IGF-I is the only  form of IGF-I which is able to directly 99 
stimulate the IGF-IR [38] (See Figure 1 for more details). Activation of the insulin-like growth factor-I 100 
receptor (IGF-IR ) by free IGF-I  stimulates  multiple  pathways  which finally results in multiple  biological 101 
effects in a variety of tissues and cells (Figure 2).                                                                                                                                                                  102 
Determination of true IGF-I bioactivity in serum and other biological fluids still presents substantial 103 
challenges. After generation of highly specific antibodies for IGF-I it became possible  to develop 104 
immunoassays for assessment of circulating IGF-I levels in serum and plasma  [29, 61, 86]. To date total 105 
IGF-I immunoassays are clinically widely used to assess circulating IGF-I bioactivity  in humans and the 106 
majority of  available literature about IGF-I is based on information obtained by use of immunoassays.   107 
As a consequence,  immunoassays are very often considered to be the most useful method to assess the 108 
amount of circulating IGF-I that is biologically active in the body. However, in the following paragraphs 109 
several arguments will be discussed, which will challenge this view.                                                                                                                                                               110 
A major technical problem encountered when measuring  circulating IGF-I by immunoassays is 111 
interference of IGFBPs.  Presence of IGFBPs in a blood sample may significantly disturb reactions 112 
between IGF-I and antibodies in the tube  and this may  result in spurious estimates of the total amount 113 
of IGF-I present in that sample. Therefore, most available IGF-I immunoassays use an extraction step to 114 
remove all IGFBPs prior to the measurement in order to guarantee full accessibility to IGF-I of highly 115 
specific antibodies targeting IGF-I [15]. However, by removing all IGFBPs before measurement of IGF-I 116 
(potentially) modulating effects of IGFBPs and IGFBP proteases on IGF-IR stimulating activity  (IRSA)  are 117 
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also eliminated [54]. Thus, as a direct consequence of the just discussed pre-analytical procedure,  total 118 
IGF-I immunoassays are unable to produce any information about directly modulating effects of IGFBPs 119 
or IGFBP-proteases on IRSA.                                                                                                                                                                                   120 
Moreover, total IGF-I immunoassays determine the immuno-reactive properties of circulating IGF-I-like 121 
molecules, rather than the direct (stimulating) effects  of these molecules on the IGF-IR [5].  In addition, 122 
total IGF-I immunoassays may recognize  IGF-I isoforms that  are less bioactive and able to stimulate the 123 
IGF-IR than wild type  IGF-I [5].  Moreover,  fragments of IGF-I that lack biological actions, may still 124 
harbor epitopes that can be recognized by antibodies targeted to IGF-I  and be measured as intact IGF-I 125 
by  total  IGF-I immunoassays [5].  It has been further suggested that altered post-sampling integrity of 126 
IGF-I in vitro might contribute to the reported inconsistencies in circulating total IGF-I levels in literature. 127 
This latter phenomenon occurs especially under pathologic conditions [38]. Results of  total IGF-I 128 
immunoassays can be  further disturbed by presence of so called heterophilic antibodies in serum  129 
which may result in both falsely higher or lower total IGF-I levels  [6]. Despite all these limitations total 130 
IGF-I immunoassays have become popular in the last 40 years to monitor circulating IRSA in blood 131 
samples. 132 
 133 
2.The history of measuring  IRSA by bioassays 134 
Any intracellular point stimulated by binding of IGF-I to the IGF-I receptor may be utilized for the 135 
development of an IGF-I bioassay [58]. In the past a variety of tissues and cells have been used as target 136 
organs in bioassays for the determination of IRSA. Salmon and Daughhaday used the incorporation of 137 
[35S] sulphate into hypophysectomized rat cartilage [59]. Other bioassays used chicken embryo, 138 
weanling or fasted rats or porcine cartilage to assess incorporation of sulphate [32, 72, 84]. In the fat 139 
pad bioassay the conversion of [14C] glucose to CO2 was used to assess IRSA, while in another bioassay 140 
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incorporation of tritiated thymidine into DNA  of embryonic chicken fibroblasts was used [24, 53]. 141 
Although all these traditional IGF bioassays were advantageous in biological relevance, they showed 142 
certain failings in their use: lack of sensitivity, precision and specificity; in addition, high variability and 143 
long assay duration (3-6 days); comparable phenotypic responses could be the consequence of 144 
activation of an alternative receptor (e.g. the insulin receptor) [33, 58].  Results of many of these 145 
traditional bioassays were sometimes also influenced by other hormones, which were present in the 146 
measured serum samples [33]. For example, it was observed that thyroid hormone (like IGF-I) could 147 
stimulate sulphate uptake in to chicken embryo cartilage whereas cortisol was found to inhibit IGF-I-148 
mediated effects in porcine cartilage [20, 25]. Moreover, these traditional IGF bioassays did not detect 149 
specifically the IRSA  in whole serum, but rather reflected the overall stimulating activity of serum for 150 
that target tissue [33]. 151 
 152 
3.The development of the IGF-I Receptor  Kinase Receptor Activation Assay (KIRA) 153 
The IGF-IR KIRA assay was developed by Michael Sadick et al. as an alternative approach for bioassays 154 
measuring IGF-IR endpoints [58]. They showed that results obtained with an IGF-IR KIRA assay in MC-7 155 
cells (with endogenous IGF-IR expression) correlated well with classical endpoint bioassays such as a 156 
[3H]thymidine incorporation assay [58]. The principle of the IGF-IR KIRA assay is based on measurement 157 
and quantification of phosphorylated tyrosine residues of the -subunit of the IGF-IR (Figure 3).  158 
Phosphorylation of tyrosine residues of the β-subunit of the IGF-IR normally starts the intracellular signal 159 
cascade after binding of IGF-I to the IGF-IR [13, 58]. The IGF-IR KIRA assay utilizes two separate 160 
microtiter plates, one for ligand stimulation of intact cells, and the other for receptor capture and 161 
phosphotyrosine ELISA [58] (Figure 3). Results obtained with the IGF-IR KIRA assays are highly 162 
reproducible [58].  Since the IGF-IR KIRA assay uses a sample incubation time of 15 minutes, time is too 163 
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short for stimulated cells to produce de novo IGFBPs that may interfere with IGF-I action during sample 164 
incubation [13]. The IGF-IR KIRA assay makes use of either endogenously expressed IGF-IR receptors or 165 
stably transfected IGF-IR receptors with a polypeptide flag (11). Frystyk et al. and Brugts et al. used an 166 
IGF-I KIRA assay with human embryonic cells transfected with a copy DNA of the full-length human IGF-167 
IR [7, 13]. By this modification the IGF-IR KIRA assay became even more sensitive than that original KIRA 168 
assay described by Sadick et al. Most likely this was due to the higher expression of IGF-IRs after 169 
transfection compared to endogenously expressed IGF-IRs  [13]. The standard curve of the IGF-I KIRA 170 
based on human embryonic kidney (HEK293) cells transfected with a copy DNA of the full-length human 171 
IGF-IR started at a concentration of 10 pmol/L (0.08 µg/L) IGF-I [13]. The IGF-IR KIRA assay was found to 172 
be specific: insulin, insulin analogs and proinsulin in physiological concentrations had almost no 173 
(stimulating) effect on the IGF-IR KIRA signal while IGF-II had a cross-reactivity of 12% [13]. In addition, it 174 
had a remarkable low intra- and inter-assay coefficient variation <15%) for a bioassay  [7]. It has been 175 
further demonstrated that the IGF-IR KIRA is a relatively rapid and reproducible method for assessing 176 
IRSA  which takes into account modifying effects of IGFBPs on the interaction between IGF-I and the IGF-177 
IR [37].                                                                                                                                                                                         178 
In the next paragraphs we will give a comprehensive overview of  the existing literature which  179 
illustrates the clinical significance of measuring IRSA by the IGF-IR KIRA assay. 180 
 181 
4. IRSA  and age 182 
To date only one study has established age-specific normative values  for IRSA as measured by the IGF-IR 183 
KIRA assay [7]. In a cross-sectional study circulating IRSA was measured in 400 healthy non-fasting blood 184 
donors aged 18-79 yrs. [7]. Circulating IRSA showed a wide inter-individual variability among subjects at 185 
every age. Like total IGF-I levels, IRSA decreased significantly with age but the decline of IRSA with age 186 
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was less steep than it was observed for circulating total IGF-I levels [7]. Due to the cross-sectional design 187 
of this latter study no information about intra-individual changes of IRSA during aging was obtained. 188 
Nevertheless the discrepant decline with age between IRSA and total IGF-I suggests that IRSA becomes 189 
less growth hormone (GH) dependent with aging than total IGF-I levels [7]. Other potential explanations 190 
for this  discrepant decline with age between IRSA and total IGF-I could be that the relative increase in 191 
IRSA with age compared to total IGF-I reflects a compensatory mechanism to overcome an age-192 
dependent relative IGF-IR resistance or that the relative contribution of IGF-II to IRSA increases with age  193 
[7].                                                                                                                                                                                In 194 
the same study a significant drop in IRSA was observed in women aged 50-60 years which was not 195 
observed for total IGF-I [7].  Women at younger ages showed higher lRSA than males but had lower IRSA 196 
than the males after the age of 50-60 years. The  decrease in estrogen levels around menopause in 197 
females might play a role in the observed drop in IRSA after the age of 50-60 years since  estrogen is well 198 
known to play an important role in regulating activity of the GH/IGF-I axis [45].                                                                   199 
IRSA as measured by the IGF-IR KIRA assay was positively related to total IGF-I but the found correlation 200 
coefficients were relatively low (r  0.50) suggesting that IRSA as measured by the IGF-IR KIRA assay 201 
produces basically different information about the IGF-I system than IGF-I immunoassays [7]. However, 202 
the physiological importance of this difference is unclear at the moment.                                                                                                                                                        203 
In another smaller cross-sectional study of men and women aged 20-70 yrs IRSA also tended to decrease 204 
to a lesser extent than total IGF-I with age [82]. However, in this latter study no significant drop of IRSA 205 
around menopause was found in females, which may be related to the lower number of participants 206 
included in this latter study [82].   207 
 208 
5. IRSA in Health 209 
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5.1 IRSA and Fasting 210 
In a small study in which in non-obese healthy subjects effects of fasting on GH signaling and action 211 
were investigated, GH levels significantly increased after 37.5 h of fasting compared to levels after the 212 
overnight fast, while (immuno-reactive) total IGF-I levels were similar under both conditions [50]. In 213 
contrast, IRSA measured by the IGF-IR KIRA assay was significantly  lower after 37.5 h of fasting 214 
compared to results following the overnight fast, whereas IGFBP-1 was significantly increased [50]. 215 
These findings are in line with Chen et al. who previously reported that after prolonged fasting 216 
reductions of total IGF-I were preceded by reductions in IRSA and free IGF-I and a simultaneous increase 217 
of IGFBP-1 levels [12]. Thus this time course suggests that the decline in IRSA was causally linked to the 218 
increase in IGFBP-1 [50]. In this latter study it was also found that IRSA compared to ultra-filtered free 219 
IGF-I was relatively less affected by fasting and it  was hypothesized that this latter finding could be 220 
explained by the fact that in contrast to the ultrafiltration method the IGF-IR KIRA assay was able to 221 
detect the concomitant increase in IGFBP-1-complexed-IGF-I [12]. 222 
 223 
5.2. IRSA and Life style factors 224 
When in a cohort of young women recruited from a local college campus the relationships between IRSA 225 
(measured by the IGF-IR KIRA assay) and life style factors were studied, IRSA was negatively associated 226 
with age, body fat percentage and habitual alcohol intake and positively associated with estradiol, 227 
progesterone and selenium intake [43]. In multivariate analysis only 61% of the variation in IRSA could 228 
be attributed to circulating concentrations of immunoreactive total and free IGF-I and IGFBP-1, IGFBP-2 229 
and IGFBP-3 [43].  It was concluded that further research is needed to better understand the biological 230 
mechanisms responsible and the consequences for the reported associations [43]. 231 
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 232 
5.3  IRSA and Exercise 233 
In healthy men circulating concentrations of IRSA (measured by the IGF-IR KIRA assay), and 234 
immunoreactive free IGF-I, total IGF-I and total IGF-II did not change after single 30 seconds sprints, 235 
despite an increase in GH concentrations [66]. Thus, a short sprint exercise may stimulate GH secretion 236 
but does not change IRSA nor IGF concentrations [66].                                                                                                                                                    237 
During a submaximal exercise (45 minutes of cycle ergometer at the lactate threshold) GH 238 
administration to adults with GH deficiency (GHD) induced minor changes in IGFBP-1, IGFBP-2 and 239 
IGFBP-3 without affecting IRSA, IGF-I, IGF-II or IGFBP-3 proteolysis [42]. Thus administration of GH to  240 
adults with GHD did not result in changes of IRSA during submaximal exercise [42].                                                                                   241 
After 8 weeks of resistance, aerobic and combined exercise training both circulating IRSA and immuno-242 
reactive IGF-I remained stable in young healthy women despite a significant improvement in  aerobic 243 
fitness, lean mass and upper and lower body strength [52].                                                                                        244 
Taken together, all these findings suggest no significant changes of IRSA during acute and chronic 245 
exercise. 246 
 247 
5.4 Effects of Insulin on IRSA 248 
During an hyperinsulinemic euglycemic clamp circulating IRSA (measured by the IGF-IR KIRA assay)  249 
acutely decreased both in controls and subjects with impaired glucose tolerance, whereas 250 
simultaneously no changes in immunoreactive total IGF-I or IGF-II were observed [1]. Similarly, IGFBP-1 251 
levels significantly decreased in both groups, whereas no changes were seen in IGFBP-3, while GH and 252 
IGFBP-2 levels significantly increased [1].  The acute insulin-induced reduction of IRSA during the clamp 253 
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occurred despite  reduction in IGFBP-1 levels, and therefore  reduction of IRSA during the clamp was 254 
explained by the concomitant increase of circulating IGFBP-2 concentrations, while the observed 255 
increase in GH concentrations during the clamp most likely were due to decreased negative feedback of 256 
circulating IRSA [1].                                                                                                                                                                            257 
In contrast  to the observed acute insulin-mediated decrease of IRSA, chronic hyperinsulinemia did not 258 
reduce circulating IRSA, which  was explained by the reduction of both IGFBP-1 and IGFBP-2 levels 259 
during long-term exposure to high insulin levels [1].  260 
 261 
5.5 Effects of Glucagon on IRSA 262 
Intramuscular glucagon administration to lean subjects, obese subjects and patients with type 1 263 
diabetes mellitus decreased circulating IRSA (measured by the IGF-IR KIRA assay) in all three groups 264 
despite no changes were observed in circulating immunoreactive total IGF-I and IGFBP-3 levels [60]. 265 
Since the reduction in IRSA occurred before the glucagon-induced surge in GH,  decreased negative 266 
feedback by IRSA provides a mechanism for the known increase in GH secretion after administration of 267 
glucagon [60].  The authors hypothesized that the decrease in IRSA after glucagon administration was 268 
related to an increase in circulating IGFBP-1 and IGFBP-2 levels which, in turn, most likely was mediated 269 
via a glucagon-mediated activation of the FOXO/mTOR pathway [60]. 270 
 271 
5.6 Effects of GLP-1 on IRSA 272 
Short-term  infusions of glucagon-like peptide-1 (GLP-1) in healthy subjects tended to increase IRSA 273 
(measured by the IGF-IR KIRA assay) and reduced IGFBP-1 levels [64]. Therefore it was suggested that 274 
IRSA in this study increased secondary to suppression of IGFBP-1 concentrations [64]. 275 
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 276 
5.7 IRSA in Serum vs. Interstitial Fluid 277 
With the suction blister technique IRSA (measured by the IGF-IR KIRA assay) was 41 % higher in 278 
interstitial fluid than IRSA in serum [22]. It was suggested that this was related to an increased 279 
enzymatic IGFBP-proteolysis and an altered composition of IGFBPs in interstitial fluid. As a consequence 280 
larger fractions of IGF-I and IGF-II were free to bind to the IGF-IR [22]. In contrast, immuno-reactive total 281 
IGF-I and IGF-II levels and IGF-binding proteins (IGFBPs) levels were approximately 50% lower in 282 
interstitial fluid than in serum [22]. Thus this study suggested that IRSA may be higher at the tissue level 283 
than in the circulation.        284 
 285 
5.8 Effects of Prednisolone on IRSA 286 
Prednisolone treatment (5mg per day during 1 week) to children with severe asthma significantly 287 
reduced IRSA (measured by the IGF-IR KIRA assay) by 12%  compared to placebo, while no changes were 288 
observed for immunoreactive total IGF-I,  free IGF-I, IGFBP-3, IGFBP-2 IGFBP-1 and IGFBP-1-bound IGF-I 289 
[28]. Prednisolone had no direct effects on IGF-IR phosphorylation. It was concluded that treatment with 290 
glucocorticoids induces a circulating substance that is able to inhibit IGF-IR activation in vitro without 291 
affecting circulating total or free IGF-I [28]. At present the nature of this substance is not identified [28]. 292 
Interestingly, more than twenty years ago existence of a circulating  inhibitor of the IGF-IR  induced by 293 
systemic glucocorticoid treatment was already hypothesized when IRSA was assessed by so called end-294 
point bioassays that measured incorporation of radiolabeled sulfate or thymidine into cultures of 295 
porcine cartilage [48, 71].                                                                                                                                                     296 
In contrast to the findings in the study just discussed, both circulating IRSA and total IGF-I steadily 297 
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increased compared to placebo when men received prednisolone in high doses (37.5 mg per day for 5 298 
days) [55]. Although prednisolone increased circulating IRSA above placebo levels, this was not 299 
translated into higher levels of IRSA in interstitial fluid (collected by the suction blister technique) [55]. 300 
Thus, short-term prednisolone administration in high doses appears to exert distinct, compartment-301 
specific effects on IRSA. The authors hypothesized that the observed increase in circulating IRSA (and 302 
total IGF-I) after prednisolone was most likely secondary to a prednisolone–mediated increase of insulin 303 
receptor resistance and IGF-IR resistance [55].  Serum obtained from participants after high dose 304 
prednisolone treatment showed reduced ability to  phosphorylate IRS-1, Akt and mTOR in IGF-IR –305 
transfected cells compared to serum after placebo, suggesting that prednisolone treatment in this high 306 
dose induced IGF-IR resistance by impeding post-IGF-IR signaling [55]. These results further support the 307 
hypothesis that glucocorticoids in high doses primarily impair anabolic actions of IGF-I by suppressing 308 
the post-receptor pathways of the IGF-IR rather than by suppressing circulating  IRSA [55]. 309 
 310 
5.9 Effects of Raloxifene and Estrogen on IRSA  311 
While the selective estrogen receptor modulator raloxifene and estrogen suppressed circulating 312 
immunoreactive total IGF-I equally in growth hormone deficiency (GHD) and growth hormone (GH)-313 
replaced hypopituitary women, neither raloxifene nor estrogen affected circulating IRSA (measured  by 314 
the IGF-IR KIRA assay), while  reduction of the total IGF-I: IGFBP-3 ratio, considered by many people as a 315 
proxy for bioavailable IGF-I, was significantly greater during  raloxifene treatment [4]. Treatment with 316 
GH significantly increased IRSA but this effect was attenuated by co-treatment with raloxifene and 317 
estrogen [4]. In addition, proportion of IRSA to total IGF-I was unaffected by any of these treatments [4]. 318 
Since during GH therapy of hypopituitary women co-treatment with raloxifene led to a smaller gain in 319 
lean body mass than GH co-treatment with estrogen, the authors concluded that the observed different 320 
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effects on lean body mass between raloxifene and estrogen treatments could not be explained by 321 
differences in IRSA [4]. 322 
 323 
6. IRSA in Disease States 324 
 325 
6.1 IRSA  and GHD 326 
Before start of GH treatment IRSA (measured by the IGF-IR KIRA assay) in adult patients with proven 327 
GHD was more frequently below the normal range (<-2 SD)  than immunoreactive total IGF-I levels (81.9 328 
vs. 61.7%, respectively) and this was especially observed in patients older than 40 years of age [79]. 329 
After start of GH treatment both IRSA and total IGF-I significantly increased but changes in IRSA did not 330 
parallel changes in total IGF-I [80]. After 12 months of GH treatment  total IGF-I normalized in 81% of 331 
patients, whereas in only 50% of patients the IRSA was in the normal reference range [80]. In addition, 332 
IRSA remained below normal in more than 40% of patients in whom total IGF-I had normalized [80].  333 
Interestingly, the increase of the IGF-I/IGFBP3 ratio  (which has been suggested to reflect an estimate of 334 
bioavailable IGF-I) after 12 months GH treatment was almost similar to the reported increase of IRSA 335 
[80].                                                                                                                                                                                     336 
IRSA was found to be positively related to QOL as assessed by the disease-specific Question on Life 337 
Satisfaction Hypopituitarism (QLS-H) module, whereas total IGF-I was not. These findings suggest that 338 
IRSA may be a more sensitive marker for changes in QOL during GH treatment of adult patients with 339 
GHD [78].  An interesting follow-up study would be to assess the use of IRSA for GH dose titration during 340 
GH treatment of adult patients with GHD.                                                                                                                         341 
Seventy-two hours after administration of a single high dose of the GH receptor blocker pegvisomant to 342 
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untreated patients with GHD circulating IRSA (measured by the IGF-IR KIRA assay) significantly 343 
decreased by 14%  and immunoreactive total IGF-I by 23 %  compared to baseline whereas basal GH 344 
levels increased, and IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 levels did not alter [85]. Nonetheless, a strong 345 
positive correlation between pegvisomant levels and circulating IGFBP-1 and IGFBP-2 levels was 346 
observed, suggesting that the modulatory effects of pegvisomant on IRSA were mediated in a dose-347 
dependent manner by concomitant increasing levels of IGFBP-1 and IGFBP-2  [62, 85]. 348 
 349 
6.2 IRSA and IUGR  350 
Cord blood immunoreactive total IGF-I and total IGF-II, and IRSA (measured by the IGF-IR KIRA assay),  351 
were lower in neonates born with intrauterine growth restriction (IUGR) than in neonates born 352 
appropriate for gestational age (AGA) [70]. IGFBP-1 concentrations were higher in IUGR neonates than 353 
in AGA neonates [70].  As IGFBP-1 is an important regulator of IRSA  this may partly explain why levels of 354 
IRSA were suppressed in IUGR neonates:  higher IGFBP-1 may sequester circulating IGF-I and thereby 355 
reduce IRSA [70]. 356 
 357 
6.3 IRSA and Acromegaly 358 
In a small study of newly diagnosed patients with active acromegaly (based on clinical presentation, 359 
unsuppressed GH levels during an OGTT, and elevated age-matched immune-reactive total IGF-I levels) 360 
IRSA (measured by the IGF-IR KIRA assay) was within the reference range in a considerable number of 361 
patients [81]. In this study, the R2 value was 0.70 suggesting that 30% of the variation in IRSA could not 362 
be explained by levels of total IGF-I, demonstrating that IRSA is only partly dependent on total IGF-I [81]. 363 
In addition, the mean percentage of IRSA over total IGF-I was 0.81% in subjects with active acromegaly 364 
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indicating that the IGF-IR KIRA assay provided fundamentally different information about the circulating 365 
IGF-I system than IGF immunoassays [81]. Age-adjusted soluble Klotho levels were significantly related 366 
to IRSA and it was hypothesized that elevated soluble Klotho levels may directly have reduced IRSA. 367 
Moreover, in this study IRSA was more strongly related to physical measures of QoL than total IGF-I, 368 
suggesting that IRSA may better reflect physical limitations perceived in active acromegaly [81].                                                                                                                                  369 
In an another study among active acromegalics circulating IRSA (measured by the IGF-IR KIRA assay) 370 
decreased significantly during treatment with pegvisomant as well as with combination treatment with a 371 
somatostatin analog and pegvisomant. However, there were no significant differences in the changes of 372 
IRSA between both treatment regimens [41]. Moreover, immunoreactive total and free IGF-I showed 373 
comparable results as obtained by IRSA [41]. 374 
 375 
6.4 IRSA and PAPP-A2 376 
The metalloproteinase pregnancy-associated plasma protein A2 (PAPP-A2) has been hypothesized to 377 
increase IGF-I bioactivity by specific cleavage of IGFBP-3 and IGFBP-5 [2]. Recently two unrelated 378 
families have been described  from whom family members presented with progressive postnatal growth 379 
failure, microcephaly, thin long bones and decreased bone density [2]. In the blood markedly elevated 380 
circulating concentrations of immunoreactive total IGF-I, IGF-II, IGFBP-3, IGFBP-5 and ALS were 381 
measured. Size-exclusion chromatography showed a significant increase of IGF-I bound in its ternary 382 
complex [17]. Spontaneous GH secretion was also markedly elevated [2]. In both families loss-of-383 
function mutations in the PAPP-A2 gene were found which resulted in undetectable PAPP-A2 activity 384 
[17]. When circulating IRSA was measured by the IGF-IR KIRA assay, IRSA was low and therefore it was 385 
hypothesized that low IRSA was responsible for the observed poor growth [2]. In favor of this latter 386 
hypothesis, short-term treatment with recombinant human IGF-I (rhIGF-I) increased  IRSA and this was 387 
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accompanied by improved growth and height in young patients with these PAPP-A2 mutations [51]. In 388 
addition, during rhIGF-I treatment spontaneous GH secretion decreased while circulating total IGF-I and 389 
IGFBP-3 levels remained elevated [51]. The decline in spontaneous GH secretion most likely resulted 390 
from a restored  negative feedback as a consequence of the rise in circulating IRSA after rhIGF-I  391 
treatment [51]. 392 
 393 
6.5 IRSA in Turner patients 394 
To overcome the retarded growth of Turner patients it has been reported that very high doses of GH are 395 
needed [73]. In untreated adult patients with Turner Syndrome IRSA (measured by the IGF-IR KIRA 396 
assay) was found to be decreased [31]. This latter result was found despite the presence of normal 397 
immuno-reactive levels of total IGF-I,   IGFBP-1, -2 and -3 and Acid Labile Subunit (ALS)  [31]. However, 398 
Western ligand blots of IGFBP-1 and-2, as well as IGFBP-4 in this study population showed signs of 399 
extensive proteolysis while the IGFBP-3 ternary complex was significantly reduced [31]. It therefore was 400 
speculated that the decreased circulating IRSA, may play a role in the reduced action of GH in Turner 401 
syndrome [31]. 402 
 403 
6.6 IRSA and Anorexia Nervosa 404 
In malnourished patients with anorexia nervosa circulating IRSA (measured  by the IGF-IR KIRA assay) , 405 
total IGF-I (immuno-reactive) and free IGF-I (ultra-filtered) were significantly decreased and IGFBP-1 406 
levels were highly increased [67]. During refeeding, a significant increase in circulating IRSA, total IGF-I 407 
and free IGF-I was observed, while BMI also increased  [67]. The circulating IRSA and total  IGF-I  showed 408 
a correlation coefficient of 0.59  suggesting that in anorexia nervosa patients 60% of variation in  IRSA 409 
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could not be explained by levels of immunoreactive total IGF-I, thus again demonstrating that IRSA is 410 
only partly dependent on total IGF-I [67].  411 
 412 
6.7 IRSA  and Obesity 413 
Despite low GH secretion and decreased IGFBP-1, 24h mean circulating IRSA (measured by the IGF-IR 414 
KIRA assay)  was not decreased in obese women [26]. In addition, IRSA did not correlate with BMI and 415 
IGFBP-1 [26]. Therefore it was concluded that these findings argue against elevated IRSA as the 416 
mechanism underlying reduced GH secretion in obesity by an augmented negative feedback.  In another 417 
cross-sectional placebo-controlled study GH administration during 6 months to overweight/obese 418 
women resulted in an increase of both circulating immunoreactive total IGF-I and IRSA (measured by the 419 
IGF-IR KIRA assay) [19]. Interestingly in this latter study the increase in IRSA rather than the increase in 420 
total IGF-I predicted the GH-related increase in lean mass and decrease in total adipose tissue/BMI [19]. 421 
  422 
6.8 IRSA and the Metabolic Syndrome 423 
In a cross-sectional study embedded in a random sample of over 1000 elderly subjects from the 424 
Rotterdam Study, a prospective population-based cohort study,  a progressive rise in circulating IRSA 425 
(measured by the IGF-IR KIRA assay) was found with increasing  insulin resistance as long as fasting 426 
blood glucose levels were within the normal range [10]. However, as soon impaired fasting blood 427 
glucose were present, circulating IRSA peaked and reached a plateau. Finally when blood glucose levels  428 
further increased and individuals  could be classified as having diabetes, circulating IRSA progressively 429 
decreased [10]. In addition, IRSA peaked when three criteria of the metabolic syndrome were present 430 
and then declined significantly when five criteria of the metabolic syndrome were present suggesting an 431 
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inverse U-shaped relationship between IRSA and number of components of the metabolic syndrome 432 
[10]. This latter finding contrasts with previous results reporting an inverse relationship between the 433 
(immunoreactive) total IGF-I/IGFBP-3 ratio and components of the metabolic syndrome [10, 63]. 434 
  435 
6.9 IRSA and Type 1 Diabetes 436 
Irrespective of pubertal status children and adolescents with type 1 diabetes showed lower IRSA 437 
(measured by the IGF-IR KIRA assay) and immunoreactive total IGF-I, but higher IGFBP-1 than healthy 438 
controls [65].  Suppression of IRSA was relatively more pronounced than total IGF-I and this latter 439 
finding was explained by the more concomitant increase of IGFBP-1 inhibiting IGF-I actions [65].                                                                                                                          440 
When comparing patients with and without residual -cell function IRSA and IGF-II as well as IGFBP-3 441 
were significantly higher in prepubertal patients with residual -cell function, supporting the hypothesis 442 
that the portal supply of insulin to the liver is an important regulator of the activity of the GH-IGF axis, at 443 
least in prepubertal children, since such relation was absent in pubertal patients [65].                                                                                                                                                      444 
Insulin plays an important role in the regulation of the GH-IGF-I axis. When comparing the GH-IGF-I axis 445 
response after a single dose human NPH insulin, insulin detemir and insulin glargine in type 1 diabetes 446 
patients, it was found that independent of the actual plasma glucose levels, IRSA (measured by the IGF-447 
IR KIRA assay) was higher and IGFBP-1 lower after insulin detemir than after NPH insulin and glargine 448 
administration, thereby explaining the lower GH levels [46]. By contrast, immunoreactive total IGF-I, 449 
IGFBP-2 and IGFBP-3 were comparable after administration of these three different insulins [46]. Since it 450 
is thought that the combination of a reduced GH secretion and an increased IRSA may have beneficial 451 
metabolic effects in type 1 diabetes, this study suggested that in this respect insulin detemir compared 452 
to NPH insulin and glargine is superior [46].                                                                                                                    453 
Ma et al. showed in type 1 diabetes patients that IRSA was more sensitive to short-term changes in 454 
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insulin exposure than total IGF-I, although the physiological significance of this observation has to be 455 
determined [47]. In this latter study again a strong inverse relationship between IRSA and circulating 456 
IGFBP-1 levels was found [47]. Moreover, despite distinct glucose-lowering properties, equal doses of 457 
human insulin, insulin aspart and two biphasic aspart preparations (BIAsp50 and BIAspo70) had similar 458 
effects on IRSA [47].                                                                                                                                                     459 
Hedman et al. studying in type 1 diabetes whether the route of insulin administration affected 460 
circulating IRSA (measured by the IGF-IR KIRA assay) found that continuous intraperitoneal insulin 461 
infusion (CIPII) induced higher circulating IRSA, but also higher circulating (immune-reactive) total IGF-I 462 
and IGF-II levels and lower IGFBP-1 than subcutaneous insulin administration [34]. This again supports 463 
the hypothesis that the route if insulin administration is important for the activity of the IGF system [34]. 464 
A low endogenous circulating IRSA is likely to augment the secretion of growth hormone, which may 465 
lead to insulin resistance and finally in an increased risk of late diabetic complications [39]. The observed 466 
higher circulating IRSA after intraperitoneal insulin administration suggests that CIPII treatment in type 1 467 
diabetes patients is better correcting alterations of the IGF system than subcutaneous insulin 468 
administration [34]. 469 
 470 
6.10 IRSA and Type 2 Diabetes                                                                                                                                                                            471 
Varewijck et al. found that IRSA (measured by the IGF-IR KIRA assay) was borderline significantly lower 472 
in patients with type 2 diabetes on metformin than in non-diabetic controls, while immunoreactive total 473 
IGF-I concentrations were significantly lower in patients with type 2 diabetes than in non-diabetic 474 
participants [77]. After 36 weeks of insulin therapy IRSA significantly decreased in patients with type 2 475 
diabetes, while serum total IGF-I concentrations remained unchanged during this period [77]. The 476 
observed decline in IRSA after 36 weeks insulin therapy is in line with a study discussed above, which 477 
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showed that hyperinsulinemia suppressed IRSA, whereas total serum IGF-I did not change [1].  In this 478 
latter study it was concluded that insulin decreased IRSA through differential modulation of IGFBPs: 479 
insulin suppressed IGFBP-4 and IGFBP-1 and increased IGFBP-2 concentrations [1].                                                                                                                                                           480 
Prior to bariatric surgery in severe obese type 2 diabetic patients IRSA (measured by the IGF-IR KIRA 481 
assay) was significantly elevated, while total IGF-I was not increased [11]. After bariatric surgery IRSA 482 
only slightly increased at 3 months and was unchanged at 12 months, while simultaneously there were 483 
no changes in total IGF-I and total IGF-II [11]. In addition, IGFBP-1 significantly increased and IGFBP-3 484 
significantly decreased and these changes continued up to 12 months [11]. The biological importance of 485 
these findings is unclear at the moment. 486 
 487 
6.11 Effects of Intensive Insulin Therapy on IRSA in the Intensive Care 488 
Upon admission at the intensive care unit immunoreactive total IGF-I levels and IRSA (measured by the 489 
IGF-IR KIRA assay) were lower and GH levels were elevated in critically ill children compared with a 490 
healthy reference population [30].  In this respect there were no differences  between children 491 
randomized to conventional insulin therapy (CIT) and to intensive insulin therapy (IIT) [30]. At day 3 of 492 
admission ITT  decreased IRSA compared to CIT, while total IGF-I levels were similar when comparing 493 
both treatment arms [30]. In addition, compared to CIT, at day 3 of admission IGFBP-3 and ALS levels 494 
were decreased and IGFBP-1 levels were increased  in  the IIT group [30]. According the authors the 495 
decreased IRSA in the  IIT group may point to aggravated GH resistance [30]. A second possible 496 
explanation for the decreased circulating IRSA may be that the IIT suppressed endogenous portal insulin 497 
levels stronger than CIT and this may have led a to decreased hepatic IGF-I production, which has 498 
resulted in a reduced IRSA [30].  The long-term functional consequences of ITT on the changes in the 499 
IGF-I system  are unclear at present and should be further investigated. 500 
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6.12 Effects of Insulin on IRSA in Very Low Birth Weight Infants  501 
In a small randomized controlled study intravenous insulin administration to very low birth weight 502 
infants throughout the first week of life improved glucose control and increased IRSA (measured by the 503 
IGF-IR KIRA assay)  compared with standard care [3]. There were trends toward faster growth in leg 504 
length and increased weight gain in the infants treated with insulin (and higher IRSA) compared with the 505 
standard care group [3]. During the 7-day study period, there were no significant differences in 506 
circulating  (immuno-reactive) total IGF-I levels between the infants treated with insulin and those 507 
receiving standard care [3]. Therefore it was concluded  that early insulin therapy increased IRSA and 508 
improved blood glucose control and this could be contributing to less morbidity among very low birth 509 
weight infants [3]. 510 
 511 
6.13  IRSA and Cushing Disease 512 
Untreated Cushing disease was characterized by normal circulating IRSA (measured by the IGF-IR KIRA 513 
assay)  and immunoreactive total IGF-I levels [74]. Treatment of patients with an active Cushing Disease 514 
with a low dose of the somatostatin analog pasireotide (which binds with high affinity to somatostatin 515 
receptors subtypes 1-3 and 5) during 28 days reduced cortisol production and normalized urinary free 516 
cortisol in 29% [74]. During treatment of pasireotide Z-scores for IRSA and total IGF-I decreased 517 
significantly to values < -2 SD in 43% and 35%, respectively, suggesting the induction of growth hormone 518 
deficiency de novo [74].     519 
 520 
6.14 IRSA and Graves Ophthalmopathy 521 
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In subjects diagnosed with Graves Ophthalmopathy values for IRSA (measured by the IGF-IR KIRA assay) 522 
were found to be low normal (Z-score: -1.5 SD  ± 0.1 SD) whereas immunoreactive total IGF-I was normal 523 
(Z-score: 0.6 ± 0.2 SD) [75]. In line with these findings it was reported more than twenty years ago that 524 
IRSA was markedly reduced in thyreotoxicosis when IRSA was assessed by measuring incorporation of 525 
radiolabeled sulfate into cultures of porcine cartilage [49].                                                                                   526 
 527 
6.15 IRSA and Kidney Disease 528 
Patients with end-stage renal disease showed elevated GH, high normal circulating immunoreactive 529 
total IGF-I and subnormal IRSA (measured by the  IGF-IR KIRA assay) compared to controls [27]. After 7 530 
days treatment with recombinant GH IRSA tended to be lower in patients with end-stage renal disease 531 
than controls while total IGF-I increased to the same extent as controls [27]. The authors suggested that 532 
the observed changes in IRSA (but not in total IGF-I) indicated that hepatic sensitivity to GH was reduced 533 
by 50 % in patients with end-stage renal disease and that in patients with end-stage renal disease 534 
changes in total IGF-I during treatment with GH are not reflecting changes in endogenous activity of IGF-535 
I [27].                                                                                                                                                                                     536 
In another study Ivarsen et al. found that directly after hemodialysis there were marked reductions in 537 
IRSA (measured by the IGF-IR KIRA)  and ultrafiltered free IGF-I in non-diabetic patients with end-stage 538 
renal disease while there were only marginal reductions in immunoreactive total IGF-I and total IGF–II 539 
[36]. They hypothesized that the decrease in IRSA was a consequence of an increase in IGFBP-1, 540 
sequestering free IGF-I, and thereby reducing IRSA [36]. In accordance with this view the increase in 541 
IGFBP-1 was accompanied by a parallel increased complex formation between IGF-I and IGFBP-1 [36]. In 542 
addition, Ivarsen et al. suggested that catabolism induced by hemodialysis may be (in part) reflected by 543 
the observed reductions in IRSA [36].  When a meal was served to patients on maintenance 544 
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hemodialysis before hemodialysis,  this resulted in a 20% maximum increase of IRSA at 120 min during 545 
hemodialysis, whereas total IGF-I levels showed a maximum increase of 5% at 180 min [56].                                                                                                                                                                                          546 
In another study by the same group, a baseline meal was offered at the day of hemodialysis [57]. In this 547 
latter study the expected postprandial increase in IRSA after a baseline meal was absent on all four 548 
study days. IRSA  only increased above baseline when a second meal was offered at the day of 549 
hemodialysis [57]. In addition, immunoreactive total IGF-I did not significantly change and remained 550 
fairly constant on all four study days [57]. The increase in IRSA after the second meal on the day of 551 
hemodialysis suggested a beneficial effect of frequent meals for  patients on maintenance hemodialysis  552 
[57].                                                                                                                                                                                       553 
Brugts et al. studied patients with end stage renal disease treated on continuous ambulatory peritoneal 554 
dialysis (CAPD) and found that circulating IRSA (measured by the IGF-IR KIRA assay) increased both after 555 
administration of a dialysate with a mixture of amino acids plus glucose or a dialysate that contained 556 
only glucose while no changes in circulating immunoreactive total IGF-I levels were observed (Figure 5) 557 
[8]. Therefore they concluded that circulating IRSA rather than total IGF-I is involved in acute responses 558 
to nutritional interventions in patients with end stage renal disease treated on CAPD [8].                   559 
                                                                                                            560 
6.16 IRSA and Liver Cirrhosis  561 
Circulating IRSA (measured by the IGF-IR KIRA assay), immunoreactive total IGF-I and total IGF-II were 562 
reduced in patients with alcoholic liver cirrhosis compared to controls, whereas IGFBP-1, IGFBP-2 and 563 
the soluble IGF-II receptor were elevated [40].  Interestingly, the IRSA was fourfold elevated in ascites as 564 
compared with serum while in contrast, all other IGF-I-related peptides but pro-IGF-II in ascites were 565 
reduced as compared with serum  [40]. Thus this study suggested that in contrast to immunoreactive 566 
total IGF-I levels,  IRSA can be higher in fluids from an extravascular compartment than in serum. 567 
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However, the pathophysiological significance of these findings remains to be clarified [40].                                                                                                                              568 
In another study circulating IRSA (measured by the IGF-IR KIRA assay) significantly decreased in patients 569 
with liver cirrhosis after an oral glucose tolerance test (OGTT) and the same tendency was observed in 570 
healthy subjects [14]. This reduction of IRSA in patients with liver cirrhosis occurred despite unchanged 571 
concentrations of (immunoreactive) total IGF-I and free IGF-I [14]. It was hypothesized that the 572 
reduction of IRSA in patients with liver cirrhosis during an OGTT was related to higher levels of IGFBP-1 573 
and a faster disappearance of IGFBP-1 bound IGF-I [14].                                                                                                                                                   574 
Treatment  of patients with liver cirrhosis with a transjugular intrahepatic porto-systemic shunt (TIPS) 575 
may induce anabolism [35].  Holland-Fischer et al. found that the body cell mass of patients with liver 576 
cirrhosis increased after TIPS [35]. However, circulating concentrations of IRSA (measured by the IGF-IR 577 
KIRA assay), immunoreactive total IGF-I, total IGF-II and IGF-binding proteins did not change, suggesting 578 
that other mechanisms than activity of the IGF system are involved in the anabolic effects of TIPS [35].    579 
 580 
6.17 IRSA and Hepatocellular Carcinoma (HCC) 581 
Circulating IRSA (measured by the IGF-IR KIRA assay)  in patients with hepatocellular carcinoma was 582 
twice as high as found in patients with liver cirrhosis [21]. However, IRSA levels in both groups were 583 
markedly below the concentrations observed for healthy controls [21]. Similar patterns as found for 584 
circulating IRSA were observed for circulating immunoreactive total IGF-I, IGF-II and IGFBP-3 whereas 585 
pro-IGF-II and the IGF-I to IGFBP-3 ratio showed less pronounced but nevertheless significant differences 586 
[21]. Changes in tumor burden after treatment did not affect IRSA or IGF-II [21].  It was concluded that 587 
the observed differences in parameters of the IGF system between patients with hepatocellular 588 
carcinoma, liver cirrhosis and healthy subjects were mainly explained by variations in liver status [21]. 589 
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Therefore the authors questioned the clinical utility of measuring circulating IGF variables as markers of 590 
hepatocellular carcinoma [21].   591 
 592 
6.18  IRSA, Lung Cancer and Pleural Fluid 593 
When IRSA (measured by the IGF-IR KIRA assay) and other members of  the IGF family were compared in 594 
pleural fluid and in blood from patients with lung cancer and nonmalignant lung disease, it was found 595 
that IRSA was threefold higher in pleural fluid than in corresponding serum samples, regardless of 596 
etiology [23]. In contrast immunoreactive total IGF-I concentrations did not differ between blood and 597 
pleural fluid [23]. In addition, PAPP-A, an IGFBP protease, that may cleave IGFBP-4 and IGFBP-5, was 598 
elevated in pleural fluid and it was speculated by the authors that IGFBP-proteases (inclusive PAPP-A ) 599 
were involved in the observed increase of IRSA in pleural fluid [23]. This study suggested that local 600 
factors at the tissue level may have major effects on IRSA and that local IRSA may substantially differ 601 
from that measured in the circulation [23].  602 
 603 
6.19  IRSA, Ovarian Carcinoma and Ascites 604 
As discussed above, PAPP-A may stimulate IGF-I action through proteolysis of IGFBP-4  and in 605 
experimental animal models it has been found that PAPP-A may accelerate ovarian tumor growth by 606 
releasing IGF-I [69].  IRSA (measured by the IGF-IR KIRA assay) in ascites of patients with ovarian cancer 607 
was 31% higher than in serum [69]. In contrast, concentrations of immunoreactive total IGF-I were 608 
similar in serum and ascites, while levels of IGF-II and IGFBP-3 were decreased in ascites compared to 609 
serum [69]. Since it was found that ascites contained a 46-fold higher concentrations of PAPP-A than 610 
serum and also IGFBP-4, it was hypothesized that PAPP-A in ascites may function to increase IGF-I 611 
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actions [69]. In favor of this latter possibility it was found that ascites contained less intact IGFBP-4 than 612 
plasma and higher concentrations of proteolytically cleaved IGFBP-4 than intact IGFBP-4 [69]. 613 
 614 
6.20 IRSA and Dementia 615 
Within the Rotterdam Study higher levels of circulating IRSA (measured by the IGF-IR KIRA assay) were 616 
associated with a higher prevalence and a higher incidence of dementia suggesting that IRSA increases 617 
in response to neuropathological changes that occur in dementia [18]. Similar associations were found 618 
for Alzheimer's disease and in persons without diabetes mellitus [18]. Unfortunately in this latter study 619 
no circulating immunoreactive total  IGF-I levels were measured. As a consequence it was impossible to 620 
compare whether in this respect there existed discrepancies between IRSA and total IGF-I.  621 
 622 
6.21 IRSA and Longevity 623 
IRSA as measured by the IGF-IR KIRA assay, immunoreactive total IGF-I and the IGF-I/IGFBP-3 ratio were 624 
all three significantly lower in centenarians' offspring compared to offspring matched-controls [83]. In 625 
addition, IRSA in centenarians' offspring was inversely related to insulin sensitivity [83]. Interestingly, it 626 
was further found that in contrast to circulating total IGF-I levels, mean IRSA was comparable between 627 
centenarians and their offspring [83].  However, further studies are needed to understand the precise 628 
role of IRSA  in the modulation of the human aging process [83]. 629 
 630 
6.22  IRSA and Mortality 631 
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In a prospective observational of more than 400 healthy elderly men (aged 73-94 yrs.) IRSA (measured 632 
by the IGF-IR KIRA assay) accounted for 2.5 % (range 0.2-5.9%) of circulating (immunoreactive) total IGF-633 
I levels whereas free IGF-I (measured by immunoassay) accounted for 0.7% [9]. These findings suggested 634 
that IRSA was most likely reflecting stimulation of the IGF-IR by free IGF-I and free IGF-II and IGFs 635 
dissociated from the IGFBPs during incubation of serum samples [9]. Survival of these elderly men in the 636 
highest quartile of IRSA was significantly better than in the lowest quartile, both in the total study group 637 
(Figure 6) as well as in subgroups having a medical history of cardiovascular disease or a high 638 
inflammatory risk profile [9]. Such relationships were not observed for immunoreactive total or free IGF-639 
I [9]. Thus this study suggested that a relatively high circulating IRSA in elderly men of  73-94 yrs may be 640 
associated with extended survival and with reduced cardiovascular risk [9].  641 
 642 
7.Discussion and conclusions 643 
The main reason for using immunoassays as an estimate of circulating IGF-I bioactivity has long been the 644 
lack of reliable IGF-I bioassays  [58].  The measurement of IRSA by the IGF-IR KIRA assay has opened a 645 
completely new era and is a novel tool to asses circulating IGF-I bioactivity under conditions that mimic 646 
the in vivo cellular environment as good as possible. In this review many studies are discussed showing 647 
that measuring IRSA often produces other information in detecting changes of the IGF system than the 648 
commonly used IGF-I immunoassays. In contrast to  IGF-I immunoassays the IGF-IR KIRA assay is 649 
sensitive for modifications of IGF-IR activation by circulating IGFBPs and IGFBP-proteases [13, 44].                             650 
This review shows that in many conditions in health and disease results for IRSA (measured by the IGF-IR 651 
KIRA assay) and circulating total immunoreactive IGF-I levels (measured by immunoassays) are 652 
discordant (Table 1) . These discrepancies are probably directly  related to fundamental differences that 653 
exists between both methods. With the IGF-IR KIRA assay all serum factors, which directly or indirectly 654 
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may phosphorylate tyrosine residues of the IGF-IR, become detectable. Moreover, the IGF-IR KIRA assay 655 
is sensitive to modulating effects of the IGFBPs on the interactions between IGF-I and the IGF-IR [13]. 656 
Thus the IGF-IR KIRA assay may give information about net overall effects of IGF-I, IGF-II, IGFBPs and 657 
IGFBP-proteases on IGF-IR activation. In contrast, levels of immunoreactive total IGF-I are mainly 658 
determined by IGF-I bound to the IGFBPs. However, it is unclear which part  of this  latter fraction  is 659 
involved in the activation of the IGF-IR since as discussed above, only IGF-I in the free state is able to 660 
stimulate directly the IGF-IR [38]. Thus  discrepancies between  IRSA (measured by the IGF-IR KIRA assay) 661 
and circulating total immunoreactive IGF-I levels (as measured by immunoassays) could be  due to 662 
stimulating effects of biological factors on the IGF-IR that may be detected by the IGF-IR KIRA assay but  663 
are not recognized by total IGF-I immunoassays. Moreover, antibodies in IGF-I immunoassays may also 664 
recognize  IGF-I molecules or fragments that are biologically inactive and unable to  stimulate the IGF-IR.  665 
Therefore Zapf et al. previously suggested that results obtained by IGF-I immunoassays should always be 666 
confirmed by IGF bioassays before conclusive statements of measured IGF-I levels on physiological or 667 
pathophysiological issues are made (87).                                                                                                                        668 
This review suggests that measurement of circulating IRSA (by the IGF-IR KIRA assay)  is  especially 669 
superior to immunoreactive total IGF-I to monitor therapeutic interventions. Although the IRSA being 670 
measured by the IGF-IR KIRA assay probably more closely reflects true bioactive IGF-I than the 671 
measurement of total IGF-I in serum by immunoassays, it is good to realize that that  the IGF-IR KIRA 672 
assay  does not capture all the post-receptor intracellular events mediated by the IGF-IR. The IGF-IR KIRA 673 
assay only quantifies IGF-IR phosphorylation of tyrosine residues. Nevertheless, it has been found that 674 
the IGF-IR KIRA assay shows  excellent correlations with the more classical endpoint bioassays [58]. Thus  675 
the IGF-IR KIRA assay in its present version does not provide information about the further intracellular 676 
propagation and  IGF-IR–mediated signal more downstream [13, 58].  On the other hand, this may be a 677 
strength of the IGF-IR KIRA assay: in so called-endpoint bioassays it is often impossible to disentangle 678 
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the relative contribution of IGF-IR mediated effects to a certain end result since there is extensive cross-679 
talk at the post-receptor level between different intracellular signaling networks which are activated by 680 
other ligands than IGF-I [68]. Moreover, many biological responses are complex and depend often on a 681 
cascade of cross-talk and post-receptor events and stimulation of the IGF-IR may activate different 682 
signaling pathways intracellularly upon receptor binding in a concentration-dependent manner (Figure 683 
2).                                                                                                                                                                                  684 
Although the signal measured by the IGF-IR KIRA assay is readily direct and specific, the IGF-IR has up to 685 
6 key tyrosine residues of which of some the role in vivo is not yet fully clear [76]. In addition, the 686 
antibody used to capture the tyrosine residues may not well recognize all residues equally well because 687 
of dependence of affinity on flanking sequence and proximity of other sites [76]. Thus the IGF-IR KIRA 688 
bioassay only provides a crude, albeit convenient, measure of kinase activation.                                                                                                          689 
Interestingly,  as discussed above, IRSA in samples from the interstitial fluid obtained by the suction 690 
blister method was almost 50% higher than in matched serum samples [22]. Moreover, IRSA was higher 691 
in ascites than in serum in patients with liver cirrhosis and in patients with ovarian cancer [14, 40]. In 692 
addition, IRSA was also higher in pleural fluid than in serum in patients with lung disease [23, 69]. Thus 693 
the amount of  IRSA present in interstitial fluid and the extravascular tissues may not only substantially 694 
differ from that measured in the circulation but that the amount of local IRSA seems not directly related 695 
to circulating IRSA. These findings suggest that it is necessary to collect information about both the 696 
paracrine (local) and endocrine (circulating) IRSA to obtain an overall impression of the role of the IGF 697 
system in health and disease.                                                                                                                                           698 
An important limitation of the IGF-IR KIRA assay in its present form is that it is more labor intensive and 699 
more expensive than total IGF-I immunoassays. It measures only the amount of IGF-I (and other ligands) 700 
that that can interact with the IGF-I receptor and activate its tyrosine kinases during a short time of 701 
incubation (15 minutes). For the future the IGF-IR KIRA assay should be further miniaturized and 702 
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automated to run many samples in a relatively short time. In addition, there should be a single 703 
universally accepted standard for the IGF-IR KIRA assay for calibration and  large pools of reference 704 
serum samples should become available to monitor the (dis)concordance in results between different 705 
laboratories using an IGF-IR KIRA assay.                                                                                                                   706 
In conclusion, the IGF-IR KIRA assay is a novel tool that has opened a new era. When studying  changes 707 
of the GH-IGF-I axis in health and disease the IGF-IR KIRA assay provides in many conditions different 708 
information about the IGF system than the commonly used total IGF-I immunoassays. The IGF-IR KIRA 709 
assay probably more closely reflects true bioactive IGF-I compared to  measurements of total IGF-I in 710 
serum by immunoassays. In health and disease IRSA measured by the IGF-IR KIRA assay was 711 
considerably higher in samples from interstitial fluid and ascites than in serum, suggesting that both 712 
local and circulating IRSA should be measured in order to get a more complete view of the role of the 713 
IGF system.  714 
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Legends 1048 
Figure 1.  1049 
Schematic overview of the IGF system. The IGF system is composed of two Insulin-like Growth Factors  1050 
IGF-I (yellow)  and IGF-II (blue), six high affinity Insulin-like Growth Factor Binding Proteins (IGFBP-1 to -1051 
6), several related IGFBPs (IGFBPrp), IGFBP proteases and two receptors; the IGF-I receptor (IGF-IR) and 1052 
the IGF-II receptor. All IGFBPs can bind both IGF-I and IGF-II (however with different binding affinity for 1053 
some). Only the unbound forms of IGFs are thought to interact with the IGF-IR and the IGF-II receptor. 1054 
The IGF-IR  can bind IGF-I with high affinity but also  IGF-II with 10-fold lower affinity. In the Figure also 1055 
insulin (red) and the insulin receptor (IR) are shown. As IGFs and insulin as well as the IGF-IR and the IR 1056 
share high sequence homology they are able to bind and activate each other’s cognate receptors but 1057 
with  considerably lower avidity (displayed  by the differences in thickness of the  arrows). Interestingly, 1058 
in the body the IGF-I and IR may form hybrids which are preferentially  activated by IGF-I. 1059 
 1060 
Figure 2  1061 
Model of the IGF-IR signaling pathway. Binding of IGF-I (or IGF-II)  to the IGF-IR results in 1062 
autophosphorylation of tyrosine residues located within the intracellular kinase domain of the IGF-IR,  1063 
being the first step in the intracellular signaling cascade. This starts the activation of multiple complex 1064 
intracellular pathways (including the RAS-ERK-MAPK pathway and the PI3K/AKT pathway) and results in  1065 
multiple  biological effects in a variety of tissues and cells in the body. 1066 
 1067 
Figure 3 1068 
Schematic overview of procedures the IGF-I Kinase Receptor Activation Assay (IGF-IR KIRA).The time to 1069 
perform the assay  assay is  4-days. On day 1 human embryonic kidney (EBNA) cells stabile transfected 1070 
with the human IGF-IR are cultured in 48 well culture plates (200,000 cells per well) in medium 1071 
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containing 10% fetal calf serum (FCS). On day 2 the medium is replaced by medium containing 0.1% 1072 
human serum albumin (HSA). A second 96 well plate is coated with an human IGF-IR capture antibody.  1073 
On day 3 cells are stimulated with serum for 15 minutes and then cells are lysed. Lysate is transferred to 1074 
the washed 96 well plate that was coated with the human IGF-IR capture antibody on day 2. On day 4 1075 
the 96 well plate is washed and a second antibody is added, which specifically recognizes 1076 
phosphorylated residues located at the kinase domains of the IGF-IR. This latter antibody contains an 1077 
europium (EUR) label so that phosphorylation of the tyrosine residues of IGF-I receptor can be 1078 
quantified in a time-resolved fluorometer. 1079 
 1080 
Figure 4. Age distribution of serum total IGF-I levels (upper panel) and IRSA (lower panel) in 94 patients 1081 
diagnosed with growth hormone deficiency (GHD) (black dots). The shaded area depicts the 95% 1082 
confidence interval in normal subjects per decade of age. IRSA in adult patients with proven GHD was 1083 
more frequently below the normal range (<-2 SD)  than total IGF-I levels.  From: IGF-I Bioactivity Better 1084 
Reflects Growth Hormone Deficiency than Total IGF-I. J Clin Endocrinol Metab. 2011;96(7):2248-2254. 1085 
doi:10.1210/jc.2011-0051.  J Clin Endocrinol Metab | Copyright © 2011 by The Endocrine Society. 1086 
 1087 
Figure 5  1088 
Top: Changes in circulating total (immunoreactive) IGF-I levels in the fed state after a dialysate that only 1089 
contained glucose  (G) and after a dialysate containing aminoacids and glucose ( AA and G), respectively 1090 
(basal state = 100%). Bottom: Changes in circulating IRSA in the fed state compared to baseline after G 1091 
and after AA and G dialysate, respectively (basal state = 100%). Circulating IRSA increased both after 1092 
administration of a dialysate with a mixture of amino acids plus glucose or a dialysate that contained 1093 
only glucose while no changes in circulating total (immunoreactive) IGF-I levels were observed. From: 1094 
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Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD 1095 
patients Nephrol Dial Transplant. 2009;25(3):940-946. doi:10.1093/ndt/gfp576.Nephrol Dial Transplant 1096 
| © The Author 2009. Published by Oxford University Press on behalf of ERA-EDTA. 1097 
 1098 
 1099 
Figure 6 1100 
Cox proportional hazard plots (percent) showing Cumulative Survival for groups of circulating 1101 
(immunoreactive) total IGF-I levels (A), circulating (immunoreactive) free IGF-I levels (B) and IRSA levels 1102 
as measured by the IGF-IR KIRA assay(C). P for trend reached statistical significance only in the IRSA 1103 
group as measured by the IGF-IR KIRA assay. Groups of IRSA are shown as follows: group 1 (—), ≤25th 1104 
percentile; group 2–3 (– – –), between 25th and 75th percentile; and group 4 (—•—), ≥75th percentile. 1105 
Trends across IGF-I bioactivity risk groups were based on Cox proportional hazard models with linear 1106 
effect of the risk factor (Armitage trend test). Maximum time of follow-up was 103 months. See also 1107 
text. From: Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men Is Associated with 1108 
Increased Mortality. J Clin Endocrinol Metab. 2008;93(7):2515-2522. doi:10.1210/jc.2007-1633.  J Clin 1109 
Endocrinol Metab | Copyright © 2008 by The Endocrine Society. 1110 
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